<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Pathog</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plospath</journal-id><journal-title-group><journal-title>PLoS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4607508</article-id><article-id pub-id-type="pmid">26468873</article-id><article-id pub-id-type="doi">10.1371/journal.ppat.1005158</article-id><article-id pub-id-type="publisher-id">PPATHOGENS-D-15-00768</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma</article-title><alt-title alt-title-type="running-head">Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Abate</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ambrosio</surname><given-names>Maria Raffaella</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mundo</surname><given-names>Lucia</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Laginestra</surname><given-names>Maria Antonella</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fuligni</surname><given-names>Fabio</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rossi</surname><given-names>Maura</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zairis</surname><given-names>Sakellarios</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gazaneo</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>De Falco</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lazzi</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bellan</surname><given-names>Cristiana</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rocca</surname><given-names>Bruno Jim</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Amato</surname><given-names>Teresa</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marasco</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Etebari</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ogwang</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Calbi</surname><given-names>Valeria</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ndede</surname><given-names>Isaac</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Kirtika</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chumba</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Piccaluga</surname><given-names>Pier Paolo</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pileri</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff008"><sup>8</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Leoncini</surname><given-names>Lorenzo</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Rabadan</surname><given-names>Raul</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Systems Biology, Columbia University College of Physicians and Surgeons, New York, New York, United States of America</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Department of Biomedical Informatics, Columbia University College of Physicians and Surgeons, New York, New York, United States of America</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Department of Medical Biotechnologies, Section of Pathology, University of Siena, Siena, Italy</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy</addr-line></aff><aff id="aff005"><label>5</label><addr-line>School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom</addr-line></aff><aff id="aff006"><label>6</label><addr-line>Lacor Hospital, Gulu, Uganda</addr-line></aff><aff id="aff007"><label>7</label><addr-line>Moi University, Eldoret, Kenya</addr-line></aff><aff id="aff008"><label>8</label><addr-line>Unit of Haematopathology, European Institute of Oncology, Milan and Bologna University School of Medicine, Bologna, Italy</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Lieberman</surname><given-names>Paul M</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Wistar Institute, UNITED STATES</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: FA RR SZ LL SP PPP. Performed the experiments: LM MRA SG GDF CB TA SL BJR ME. Analyzed the data: FA SZ RR. Contributed reagents/materials/analysis tools: SP LL. Wrote the paper: FA RR LL SP SZ. Contributed clinical samples: MO VC IN KP DC. Analyzed Sequenom data: PPP MAL MR FF EM.</p></fn><corresp id="cor001">* E-mail: <email>stefano.pileri@unibo.it</email>, <email>stefano.pileri@ieo.it</email> (SP); <email>lorenzo.leoncini@dbm.unisi.it</email> (LL); <email>rr2579@cumc.columbia.edu</email> (RR)</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2015</year></pub-date><volume>11</volume><issue>10</issue><elocation-id>e1005158</elocation-id><history><date date-type="received"><day>30</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2015</year></date></history><permissions><copyright-year>2015</copyright-year><copyright-holder>Abate et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="ppat.1005158.pdf"/><abstract><p>Endemic Burkitt lymphoma (eBL) is primarily found in children in equatorial regions and represents the first historical example of a virus-associated human malignancy. Although Epstein-Barr virus (EBV) infection and <italic>MYC</italic> translocations are hallmarks of the disease, it is unclear whether other factors may contribute to its development. We performed RNA-Seq on 20 eBL cases from Uganda and showed that the mutational and viral landscape of eBL is more complex than previously reported. First, we found the presence of other herpesviridae family members in 8 cases (40%), in particular human herpesvirus 5 and human herpesvirus 8 and confirmed their presence by immunohistochemistry in the adjacent non-neoplastic tissue. Second, we identified a distinct latency program in EBV involving lytic genes in association with <italic>TCF3</italic> activity. Third, by comparing the eBL mutational landscape with published data on sporadic Burkitt lymphoma (sBL), we detected lower frequencies of mutations in <italic>MYC</italic>, <italic>ID3</italic>, <italic>TCF3</italic> and <italic>TP53</italic>, and a higher frequency of mutation in <italic>ARID1A</italic> in eBL samples. Recurrent mutations in two genes not previously associated with eBL were identified in 20% of tumors: <italic>RHOA</italic> and <italic>cyclin F</italic> (<italic>CCNF</italic>). We also observed that polyviral samples showed lower numbers of somatic mutations in common altered genes in comparison to sBL specimens, suggesting dual mechanisms of transformation, mutation versus virus driven in sBL and eBL respectively.</p></abstract><abstract abstract-type="summary"><title>Author Summary</title><p>Burkitt lymphoma is endemic in sub-Saharan Africa and affects primarily children of age 4&#x02013;7 years. Historically, it was one of the first tumors associated with a virus (EBV) and bearing a translocation involving an oncogene, i.e. <italic>MYC</italic>. There are three distinct clinical variants of Burkitt lymphoma according to the World Health Organization: sporadic, endemic and immunodeficiency-related. Although there has been some recent work on the molecular characterization of sporadic Burkitt lymphomas, little is known about the pathogenesis of endemic cases. In this work, we analyzed 20 samples of RNASeq from Burkitt lymphoma collected in Lacor Hospital (Uganda, Africa) and validated in an extension panel of 73 samples from Uganda and Kenya. We identify the presence in the adjacent non-neoplastic tissue of other herpesviridae family members in 53% of the cases, namely cytomegalovirus (CMV) and Kaposi sarcoma herpesvirus (KSHV). We also demonstrate expression of EBV lytic genes in primary tumor samples and find an inverse association between EBV lytic expression and <italic>TCF3</italic> activity. When studying the mutational profile of endemic Burkitt tumors, we find recurrent alterations in genes rarely mutated in sporadic Burkitt lymphomas, i.e. <italic>ARID1A</italic>, <italic>CCNF</italic> and <italic>RHOA</italic>, and lower numbers of mutations in genes previously reported to be commonly mutated in sporadic cases, i.e. <italic>MYC</italic>, <italic>ID3</italic>, <italic>TCF3</italic>, <italic>TP53</italic>. Together, these results illustrate a distinct genetic and viral profile of endemic Burkitt lymphoma, suggesting a dual mechanism of transformation (mutation versus virus driven in sBL and eBL respectively).</p></abstract><funding-group><funding-statement>This work was supported by grants from the Italian Association for Cancer Research (AIRC 5x1000, n. 10007) and Programma Strategico &#x0201c;Innovative approaches to the diagnosis and pharmacogenetic based therapies of primary hepatic tumours, peripheral B and T &#x02013; cell lymphomas and lymphoblastic leukaemias&#x0201d;, Programma di Ricerca Regione-Universit&#x000e0; 2010&#x02013;2012: Area 1 &#x0201c;Ricerca Innovativa&#x0201d; (SP); MIUR 2012 (LL); Steward Foundation and NIH 1 U54 CA121852-05 (RR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="0"/><page-count count="21"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>RNA-Seq data have been deposited at the NCBI SRA service (accession number PRJNA292327).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>RNA-Seq data have been deposited at the NCBI SRA service (accession number PRJNA292327).</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Burkitt lymphoma (BL) is the first human cancer to be associated with the Epstein-Barr virus (EBV), the first tumor to exhibit a chromosomal translocation activating an oncogene (<italic>MYC</italic>), and the first lymphoma to be associated with human immunodeficiency virus (HIV) infection. The World Health Organization[<xref rid="ppat.1005158.ref001" ref-type="bibr">1</xref>] classification describes three clinical variants of BL: endemic, sporadic, and immunodeficiency-related. These variants are similar in morphology, immunophenotype, and genetics. While the sporadic variant (sBL) occurs outside of Africa and is rarely associated with EBV infection, the endemic variant (eBL) arises mainly in Africa and is associated with malaria endemicity and EBV infection in almost all cases. Epidemiological studies have shown that malaria and EBV combined do not fully explain the distribution of eBL in high risk regions[<xref rid="ppat.1005158.ref002" ref-type="bibr">2</xref>]. Malaria and EBV are in fact ubiquitous within the lymphoma belt of Africa, suggesting that other etiologic agents may be involved[<xref rid="ppat.1005158.ref003" ref-type="bibr">3</xref>]. However, it is unclear what other epidemiological factors could play a role in the genesis of eBLs.</p><p>Three types of EBV latency have been described in EBV-related lymphomas according to the pattern of EBV nuclear antigen (EBNA) and the latent membrane protein (LMP) expression, namely latency I, II, and III[<xref rid="ppat.1005158.ref004" ref-type="bibr">4</xref>]. Specifically, latency I is usually associated with eBL and it denotes a transcriptional program in which an EBV infection does not produce virions and expresses a single protein, EBNA-1. While the latency I program has been extensively characterized <italic>in vitro</italic>, a different form of latency has been recently reported in 15% of eBL that uses a different set of promoters. Termed Wp-restricted latency[<xref rid="ppat.1005158.ref005" ref-type="bibr">5</xref>], this program shows a homogeneous host expression signature[<xref rid="ppat.1005158.ref006" ref-type="bibr">6</xref>] characterized by down-regulation of <italic>BCL-6</italic> and up-regulation of <italic>IRF-4</italic> and <italic>BLIMP-1</italic>. Other reports have described latency program heterogeneity at single cell level[<xref rid="ppat.1005158.ref007" ref-type="bibr">7</xref>] and low expression of <italic>LMP</italic> genes in a fraction of cases[<xref rid="ppat.1005158.ref008" ref-type="bibr">8</xref>,<xref rid="ppat.1005158.ref009" ref-type="bibr">9</xref>]. Heterogeneous EBV transcription profiles with LMP expression have been recently reported in some cases of AIDS-related and sporadic BL[<xref rid="ppat.1005158.ref010" ref-type="bibr">10</xref>], but extensive data on endemic cases are not available yet. These studies indicate that the transcriptional EBV programs of primary eBL could be more complex than expected across cases and within individuals. Therefore, the exact role of EBV has remained elusive and further investigation is required.</p><p>The genetic hallmark of all three clinical variants of BL is the t(8;14) translocation involving the juxtaposition of the immunoglobulin heavy chain locus (IGH) with the <italic>MYC</italic> oncogene[<xref rid="ppat.1005158.ref011" ref-type="bibr">11</xref>]. However, although transgenic mice expressing <italic>MYC</italic> under the control of the intronic <italic>IGH</italic> enhancer (E&#x003bc;) develop B cell lymphomas[<xref rid="ppat.1005158.ref012" ref-type="bibr">12</xref>], successive molecular characterization demonstrated that this model does not fully recapitulate the human disease. The comparison between the gene expression profile (GEP) of BL and diffuse large B-cell lymphoma (DLBCL) highlighted a distinct signature of BL characterized by the expression of both <italic>MYC</italic> targets and germinal-center B-cell genes[<xref rid="ppat.1005158.ref013" ref-type="bibr">13</xref>]. Furthermore, hypermutation and different breakpoint patterns of <italic>IGH/MYC</italic> translocation[<xref rid="ppat.1005158.ref014" ref-type="bibr">14</xref>,<xref rid="ppat.1005158.ref015" ref-type="bibr">15</xref>] suggests that the origin of human BL derives from aberrant class switching in the germinal center (GC), while transgenic <italic>IGH/MYC</italic> mice typically arise from precursor/naive B-cells. The more accurate <italic>PI3K/MYC</italic> transgenic mouse model by Sander <italic>et al[<xref rid="ppat.1005158.ref016" ref-type="bibr">16</xref>]</italic> better recapitulates the human phenotype of BL and highlights the importance of the PI3K pathway in the disease. Moreover, GEP analysis has demonstrated that the transcriptional profile of eBL is different from that observed in sBL[<xref rid="ppat.1005158.ref017" ref-type="bibr">17</xref>]. Recent studies have unveiled the genetic landscape of sBL characterized by mutations affecting the B-cell receptor (BCR) pathway and in particular the transcription factor <italic>TCF3</italic>, its negative regulator <italic>ID3</italic>, the cell-cycle G1/S regulator <italic>CCND3</italic>[<xref rid="ppat.1005158.ref018" ref-type="bibr">18</xref>,<xref rid="ppat.1005158.ref019" ref-type="bibr">19</xref>], and the chromatin-remodeling gene <italic>ARID1A</italic>[<xref rid="ppat.1005158.ref020" ref-type="bibr">20</xref>]. On the contrary, very little is known about the spectrum of alterations in eBL, how it might differ from that of sBL, the correlations between host mutation and viral infection, and the specific viral/host transcriptional programs.</p><p>In this study, we aim to characterize the presence of other potential agents, to define the EBV transcriptional profile and to link these profiles to the mutational status of new and previously reported genes. We provide a characterization of the mutational and viral landscape of eBL using 20 cases from Uganda. RNA-Seq, in combination with targeted sequencing technology on a larger cohort of cases, allows the identification, validation and assessment of the recurrence of new somatic mutations. In addition, in contrast with earlier microarray-based expression studies, RNA-Seq provides the opportunity to identify and associate microbial and tumor mutational and expression profiles.</p></sec><sec sec-type="results" id="sec002"><title>Results</title><sec id="sec003"><title>Endemic BL is associated with multiple viral infections</title><p>To identify new pathogens in eBL, we applied Pandora, a new pipeline for the characterization of tumor microbiomes, to a discovery cohort of 20 RNA-Seq samples. We established a read cutoff on the basis of those samples that tested positive for RNA <italic>in situ</italic> hybridization (ISH) of the EBER transcript. Since ISH validated all the RNA-Seq samples as positive, we established the threshold to call a virus present in a particular sample as the minimal number of reads detecting EBV (<xref rid="ppat.1005158.s001" ref-type="supplementary-material">S1 Fig</xref>). Next, we established the EBV subtype by aligning RNA-Seq reads to the genomes of both EBV type I and type II and deduced type I as the closest genotype. In addition to EBV, RNA-Seq revealed the presence of other viruses. In particular, 5/20 cases contained human herpesvirus 5 (HHV5, cytomegalovirus, CMV), 4/20 human herpesvirus 8 (HHV8, Kaposi sarcoma herpes virus, KSHV), and 1/20 human T-lymphotropic virus 1 (HTLV-1) (<xref rid="ppat.1005158.g001" ref-type="fig">Fig 1A</xref>, <xref rid="ppat.1005158.s002" ref-type="supplementary-material">S2 Fig</xref> and <xref rid="ppat.1005158.s003" ref-type="supplementary-material">S3 Fig</xref>). Human immunodeficiency virus (HIV) was not detected in any case, confirming that pediatric eBL is rarely associated with the immunodeficiency syndrome[<xref rid="ppat.1005158.ref021" ref-type="bibr">21</xref>]. Nested PCR and immunohistochemical (IHC) analysis performed on all 20 original samples confirmed the presence of all the viruses in the discovery cohort (<xref rid="ppat.1005158.s013" ref-type="supplementary-material">S1A Table</xref>). To assess whether RNA-Seq findings generalize for EBV, CMV, KSHV, and HTLV-1, we assayed for the presence of these four viruses in 20 additional cases from western Kenya by IHC (<xref rid="ppat.1005158.s013" ref-type="supplementary-material">S1B Table</xref>). In this Kenyan cohort, EBV was detected in 20/20 samples, CMV in 8/20 samples (<xref rid="ppat.1005158.g001" ref-type="fig">Fig 1B</xref> and <xref rid="ppat.1005158.s004" ref-type="supplementary-material">S4 Fig</xref>), KSHV in 7/20 samples (<xref rid="ppat.1005158.g001" ref-type="fig">Fig 1C and 1D</xref>, and <xref rid="ppat.1005158.s005" ref-type="supplementary-material">S5 Fig</xref>), and HTLV-1 in 0/20 samples. Therefore, over the 40 cases, we report the overall viral infection frequencies of 40/40 (100%) for EBV, 13/40 (32.5%) for CMV, 11/40 (27.5%) for KSHV, and 1/40 (2.5%) for HTLV-1. IHC analysis demonstrated the presence of CMV in the stromal cells and macrophages localized within the tumors and in the adjacent reactive lymphoid tissue (<xref rid="ppat.1005158.g001" ref-type="fig">Fig 1B</xref>, <xref rid="ppat.1005158.s002" ref-type="supplementary-material">S2 Fig</xref> and <xref rid="ppat.1005158.s004" ref-type="supplementary-material">S4 Fig</xref>). KSHV was identified not only in normal B-lymphocytes and endothelial cells from the adjacent reactive lymphoid tissue (<xref rid="ppat.1005158.s003" ref-type="supplementary-material">S3 Fig</xref> and <xref rid="ppat.1005158.s005" ref-type="supplementary-material">S5 Fig</xref>), but also in one case in about 5&#x02013;10% of neoplastic cells (<xref rid="ppat.1005158.g001" ref-type="fig">Fig 1C and 1D</xref>). HTLV-1 was detected in reactive T-lymphocytes in the only positive case of the discovery cohort. Sections of the samples incubated with the secondary antibody alone and sections of reactive lymphoid tissue were used as negative controls. Sections of lymph nodes with infectious mononucleosis were used as positive control for EBV. Next, we compared the viral landscape of endemic and sporadic cases by analyzing 27 RNA-Seq sBL samples from Schmitz <italic>et al</italic>.[<xref rid="ppat.1005158.ref019" ref-type="bibr">19</xref>] with Pandora. The analysis showed the presence of EBV and HIV respectively in 4/27 (15%) and in 1/27 (4%) cases, consistent with several literature sources[<xref rid="ppat.1005158.ref022" ref-type="bibr">22</xref>].</p><fig id="ppat.1005158.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005158.g001</object-id><label>Fig 1</label><caption><title>(A) RNA-Seq technology reveals the presence of EBV and of other viruses. In particular, 5/20 cases contain human herpesvirus 5 (CMV), 4/20 human herpesvirus 8 (KSHV), and 1/20 human T-lymphotropic virus 1 (HTLV-1). (B) Immunohistochemical evaluation demonstrates the presence of CMV in the stromal cells in the adjacent reactive lymphoid tissue. CMV stain, Original Magnification (O.M.): 40x. (C) KSHV positivity is shown, respectively in few neoplastic cells and in the endothelial cells within the neoplastic proliferation. LANA-1 (LN53 antibody), O.M.: 40x; (D) LANA-1 (AT4C11 antibody) O.M.: 40x.</title></caption><graphic xlink:href="ppat.1005158.g001"/></fig></sec><sec id="sec004"><title>Epstein-Barr virus latent and lytic infection in BL</title><p>Beyond identification of EBV presence, RNA-Seq enabled us to quantitatively analyze the viral transcriptional program. In addition to EBER-1 and EBER-2 transcripts, expression analysis of the viral genes showed the expression of <italic>EBNA-1</italic>, a gene associated to latency I type, in 18/20 cases (<xref rid="ppat.1005158.g002" ref-type="fig">Fig 2A</xref>). We also detected either <italic>LMP-1</italic> or <italic>LMP-2A</italic>, characterizing the latency II type, in 13/20 samples (65%), and also EBNA-2 in 1/20 cases (5%). Interestingly, 2/20 cases (10%) were characterized by the expression of <italic>EBNA-3A/B/C/LP</italic>, together with the lytic gene <italic>BHRF-1</italic>, suggesting a Wp-restricted program[<xref rid="ppat.1005158.ref023" ref-type="bibr">23</xref>]. However, the specific analysis of EBV isoforms showed the presence of H2-HF splicing event, which is hallmark of lytic <italic>BHRF-1</italic> expression[<xref rid="ppat.1005158.ref024" ref-type="bibr">24</xref>&#x02013;<xref rid="ppat.1005158.ref026" ref-type="bibr">26</xref>](<xref rid="ppat.1005158.s006" ref-type="supplementary-material">S6 Fig</xref>). Unsupervised hierarchical clustering of expressed EBV genes demonstrated two main clusters distinguished largely by gene products involved in EBV replication (BALF-2, BCRF-1, BHRF-1, BILF-1, BMRF-1, BNLF-2a, BZLF-1). The expression of these genes suggests a non-canonical latency program of the virus with a subset of viral episomes initiating lytic reactivation[<xref rid="ppat.1005158.ref023" ref-type="bibr">23</xref>].</p><fig id="ppat.1005158.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005158.g002</object-id><label>Fig 2</label><caption><title>(A) Unsupervised hierarchical clustering of expressed EBV genes demonstrates a diversity of non-canonical latency-associated gene expression programs with a subset of viral episome initiating lytic reactivation as indicated by expression of genes corresponding to the lytic program. (B) LMP-2A is expressed by 40 to 50% of neoplastic cells. LMP-2A stain, O.M.: 40x; (C) LMP-2A expression is identified in a proportion of neoplastic cells ranging from 20 to 30%. LMP-2A stain, O.M.: 40x; (D) BZLF1/ZEBRA positivity is expressed by 5 to 10% of neoplastic cells. BZLF1/ZEBRA stain, O.M.: 40x; (E) BZLF1/ZEBRA expression is detected in few neoplastic cells. BZLF1/ZEBRA stain, O.M.: 40x; (F) BMRF-1/Ea-D expression is observed in 50% of neoplastic cells. BMRF-1/Ea-D stain, O.M.: 40x; (G) BMRF-1/Ea-D protein expression in 5% to 10% of neoplastic cells is shown. BMRF-1/Ea-D stain, O.M.: 40x; (H) BHRF-1/Ea-R staining is found in 60% of neoplastic cells. BHRF-1/Ea-R stain, O.M.: 40x; (I) BHRF-1/Ea-R is expressed in 10% of neoplastic cells. BHRF-1/Ea-R stain, O.M.: 40x.</title></caption><graphic xlink:href="ppat.1005158.g002"/></fig><p>Due to the heterogeneity of the viral transcriptional programs, we aimed to validate the latency type by performing RT-qPCR for the <italic>EBNA-1</italic>, <italic>LMP-1</italic>, <italic>LMP-2A</italic>, <italic>EBNA-2</italic>, <italic>EBNA-3C</italic>, and <italic>BHRF-1</italic> transcripts across an additional series of 26 cases from an extended cohort of samples from Kenya. <italic>EBNA-1</italic> was detected in 26/26 (100%), <italic>LMP-1</italic> and <italic>LMP-2</italic> in respectively 5/26 (20%) and 20/26 (75%) cases (<xref rid="ppat.1005158.s003" ref-type="supplementary-material">S3 Table</xref> and <xref rid="ppat.1005158.s007" ref-type="supplementary-material">S7A Fig</xref>), <italic>EBNA-2</italic> in 0/26 (0%), and the combination of <italic>EBNA-3C</italic> and <italic>BHRF-1</italic> in 4/26 (15%). These results are largely consistent with the RNA-Seq data with the exception of <italic>LMP-1</italic> that has been detected at higher frequency in RNA-Seq (<xref rid="ppat.1005158.s014" ref-type="supplementary-material">S2 Table</xref>). Next, we evaluated the lytic cycle activation and found <italic>BILF-1</italic>, <italic>BALF-4</italic>, and <italic>LF-2</italic> in all 26 cases, whereas we observed the expression of <italic>BALF-2</italic> in 23/26 (90%), <italic>BHRF-1</italic> in 20/26 (80%), <italic>BZLF-1</italic> and <italic>BMRF-1</italic> in 15/26 (60%), <italic>BNLF-2a</italic> in 13/26 (50%), and <italic>BCRF-1</italic> in 11/26 (45%) of the cases (<xref rid="ppat.1005158.s003" ref-type="supplementary-material">S3 Table</xref> and <xref rid="ppat.1005158.s007" ref-type="supplementary-material">S7B&#x02013;S7D Fig</xref>).</p><p>We then validated the expression of all the available encoded-proteins by IHC using stringent positive and negative controls as reported in Materials and Methods. Overall, IHC evaluation confirmed a non-canonical latency associated program with the expression of some proteins characterizing latency II (i.e. LMP-1 in 2/26 and LMP-2A in 17/26 of the cases); however, there was heterogeneity in the intensity of protein staining and in the proportion of positive tumor cells. LMP-1 was detected in few cells, whereas LMP-2A was identified in a proportion of cells ranging from 25% to 50% (<xref rid="ppat.1005158.g002" ref-type="fig">Fig 2B and 2C</xref>). EBV replication was assessed by nuclear expression of the immediate-early BZLF-1/ZEBRA and early BMRF-1/Ea-D, BHRF-1/Ea-R lytic proteins (<xref rid="ppat.1005158.g002" ref-type="fig">Fig 2D&#x02013;2I</xref>). There was positive staining in the neoplastic cells for BZLF1, BHRF-1/Ea-R and BMRF-1/Ea-D, respectively in 11/26 (40%), 16/26 (60%), and 13/26 (50%) of the cases (<xref rid="ppat.1005158.s015" ref-type="supplementary-material">S3 Table</xref>).</p><p>Finally, we compared the patterns of latent and lytic gene expression between endemic and sporadic BLs using the 4 EBV-positive sBLs of the 27 RNA-Seq samples from Schmitz <italic>et al</italic>.<sup>16</sup> We observed the expression of <italic>BHRF-1</italic> and <italic>BMRF-1</italic> in 1 case; <italic>BZLF-1</italic> was present in 2 cases and <italic>LMP-2A</italic> in 4 cases.</p></sec><sec id="sec005"><title>Mutational landscape of eBL and correlation with EBV presence</title><p>To identify the genes that are somatically mutated in eBL, we applied the SAVI algorithm[<xref rid="ppat.1005158.ref027" ref-type="bibr">27</xref>] to the cohort of 20 RNA-Seq samples (see <xref rid="sec007" ref-type="sec">Material and Methods</xref> for gene selection criteria). Our analysis identified 13 genes recurrently mutated in more than 4 samples. We confirmed the presence of mutations in genes previously reported in BL literature[<xref rid="ppat.1005158.ref018" ref-type="bibr">18</xref>,<xref rid="ppat.1005158.ref019" ref-type="bibr">19</xref>,<xref rid="ppat.1005158.ref028" ref-type="bibr">28</xref>] (<xref rid="ppat.1005158.g003" ref-type="fig">Fig 3A&#x02013;3C</xref> and <xref rid="ppat.1005158.s016" ref-type="supplementary-material">S4 Table</xref>), including <italic>MYC</italic> in 10/20 (50%), <italic>DDX3X</italic> in 7/20 (35%), <italic>ID3</italic> in 6/20 (30%), <italic>ARID1A</italic> in 5/20 (25%), <italic>RHOA</italic> in 4/20 (20%), <italic>TCF3</italic> and <italic>TP53</italic> in 3/20 (15%), <italic>CCND3</italic> in 1/20 (5%) of the cases. In addition, we found recurrent mutations in one gene not reported so far: <italic>CCNF</italic>, detected in 4 out of the 20 cases (20%). Since <italic>RHOA</italic> mutations have not been previously detected in eBL and <italic>CCNF</italic> mutation was a new discovery, their prevalence as specific mutations was further assessed using Sequenom technology on an extended panel of 66 neoplastic samples <italic>plus</italic> 7 cases with matched normal controls (<xref rid="ppat.1005158.s008" ref-type="supplementary-material">S8A and S8B Fig</xref>). Recurrent mutations in <italic>RHOA</italic> were found in 6/73 eBL cases (8%), and in 0/7 normal samples. Two of the 6 <italic>RHOA</italic> mutations occurred in paired eBL/normal cases, confirming that the alterations are somatic (<xref rid="ppat.1005158.s017" ref-type="supplementary-material">S5 Table</xref>). Recurrent mutations in codon 451 of <italic>CCNF</italic> were found in 14/73 eBL cases (19%), and in 0/7 normal samples. One of the 14 <italic>CCNF</italic> mutations occurred in a paired eBL/normal case, showing that also <italic>CCNF</italic> alteration is somatic. Direct sequencing of genomic DNA confirmed all the mutations identified by Sequenom tecnnology and RNAseq (<xref rid="ppat.1005158.s009" ref-type="supplementary-material">S9 Fig</xref> and <xref rid="ppat.1005158.s010" ref-type="supplementary-material">S10 Fig</xref>).</p><fig id="ppat.1005158.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005158.g003</object-id><label>Fig 3</label><caption><title>(A) The presence of mutations in genes previously described in BL is reported, including <italic>MYC</italic> (50%), <italic>DDX3X</italic> (35%), <italic>ID3</italic> (30%), <italic>ARID1A</italic> (25%), <italic>RHOA</italic> (20%), <italic>TCF3</italic> and <italic>TP53</italic> (15%), and <italic>CCND3</italic> 1/20 (5%). In addition, a new mutation is shown, involving <italic>CCNF</italic> and detected in 20% of the cases. (B) Bar plot showing the frequency comparison of virus presence and driver mutations between endemic and sporadic BL. For each comparison we report the p-value associated with rejecting the null hypothesis of equal eBL and sBL prevalences. (C) Distribution of mutations in 5 driver genes. Red points indicate endemic BL, while blue points the sporadic ones.</title></caption><graphic xlink:href="ppat.1005158.g003"/></fig><p>The distribution of somatic mutations and viral presence across both eBL and sBL samples exhibit two interesting features (<xref rid="ppat.1005158.g003" ref-type="fig">Fig 3B</xref>). First, in eBL samples we observed lower mutational frequencies in the genes <italic>MYC</italic>, <italic>ID3</italic>, <italic>TCF3</italic>, <italic>DDX3X</italic>, <italic>CCND3</italic> and <italic>TP53</italic>, as compared to their reported recurrence in sBL, and higher mutational frequencies in <italic>ARID1A</italic>, <italic>RHOA</italic>, and <italic>CCNF</italic>[<xref rid="ppat.1005158.ref018" ref-type="bibr">18</xref>,<xref rid="ppat.1005158.ref019" ref-type="bibr">19</xref>]. Second, in sBL cases an almost mutual exclusivity can be seen between EBV presence and mutations in <italic>TCF3</italic>/<italic>ID3</italic> both known to be driver genes in sBL (p-value &#x0003c; 0.02, Fisher exact test). To explore this hypothesis, we performed a hierarchical clustering of both endemic and sporadic cases on <italic>TCF3</italic> target genes (previously reported in Schmitz <italic>et al</italic>.[<xref rid="ppat.1005158.ref019" ref-type="bibr">19</xref>]) and we demonstrated that the first bifurcation of the dendrogram classifies the samples into EBV-positive and EBV-negative BL independently on the specific subtype with an accuracy of 96% (45/47). (<xref rid="ppat.1005158.g004" ref-type="fig">Fig 4A</xref>). The results show that the TCF3 pathway is more activated in EBV-negative cases, as indicated by the significant negative enrichment of <italic>TCF3</italic> target genes in EBV-positive samples. Furthermore, we observe that when considering the overall panel of both endemic and sporadic BL samples, the mutually exclusivity between <italic>TCF3</italic>/<italic>ID3</italic> mutations and EBV infection yields a more significant effect (p-value &#x0003c; 0.0008, Fisher exact test). To further investigate the host transcriptional programming related to EBV presence, we performed GSEA C2 analysis on genes differentially expressed between EBV-positive and EBV-negative cases. Interestingly, we detected a significant enrichment for the <italic>LMP-1</italic> gene set signature, reported by Sengupta <italic>et al</italic>. [<xref rid="ppat.1005158.ref029" ref-type="bibr">29</xref>] in nasopharyngeal carcinoma, which is consistent with the detected <italic>LMP-1</italic> expression in RNA-Seq data (<xref rid="ppat.1005158.g004" ref-type="fig">Fig 4B</xref>). Moreover, since 13/20 RNA-Seq cases were positive for LMP2A, we investigated the role of this viral gene in the context of eBL and GSEA C2 analysis has been performed on gene differentially expressed between LMP-2A positive and LMP-2A negative samples. Interestingly, the E2F, E2F3 and cell cycle G1/S gene sets presented the highest significant enrichment score (see <xref rid="ppat.1005158.s011" ref-type="supplementary-material">S11 Fig</xref>), together with the down-regulation of retinoblastoma pathway. These results can be explained as an effect of the interaction between <italic>MYC</italic> and LMP2A. In fact, previous studies showed that LMP-2A promotes <italic>MYC</italic>-induced lymphomagenesis[<xref rid="ppat.1005158.ref030" ref-type="bibr">30</xref>], and E2F is a know target of <italic>MYC</italic> during cell division and proliferation[<xref rid="ppat.1005158.ref031" ref-type="bibr">31</xref>]. Moreover, several works associate LMP-2A expression to the PI3K/Akt pathway activation[<xref rid="ppat.1005158.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="ppat.1005158.ref035" ref-type="bibr">35</xref>] and the study from Brennan <italic>et al</italic>. (Oncogene, 2002 [<xref rid="ppat.1005158.ref036" ref-type="bibr">36</xref>]) shows that the activation of PI3K pathway in lymphoblastoid cell lines can promote E2F transcription activity to affect cell cycle and cellular proliferation.</p><fig id="ppat.1005158.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005158.g004</object-id><label>Fig 4</label><caption><title>(A) the dendrogram classifies the samples into EBV-positive and EBV-negative BL independently on the specific subtype with an accuracy of 96% (45/47). (B) GSEA C2 analysis on genes differentially expressed between EBV-positive and EBV-negative cases detects a significant enrichment for the <italic>LMP-1</italic> gene set signature. GSEA: gene set enrichment analysis.</title></caption><graphic xlink:href="ppat.1005158.g004"/></fig></sec></sec><sec sec-type="conclusions" id="sec006"><title>Discussion</title><p>Over the past few years, the concept that many diseases can be etiologically linked to infection by more than one pathogen has drawn increased attention[<xref rid="ppat.1005158.ref037" ref-type="bibr">37</xref>&#x02013;<xref rid="ppat.1005158.ref040" ref-type="bibr">40</xref>]. Whether endemic Burkitt lymphoma should also be considered a polymicrobial disease and what role genetic alterations play in the tumor are still open questions. In this paper, we analyzed the presence of pathogens other than EBV in 40 eBL primary tumors by RNA sequencing, PCR, and immunohistochemistry, and found the presence of CMV and KSHV. We detected these viruses, which are frequently reported in the African population[<xref rid="ppat.1005158.ref041" ref-type="bibr">41</xref>], primarily in the surrounding non-neoplastic tissue. Their prevalence in areas endemic for EBV, along with their absence in the sporadic cases, suggests that CMV or KSHV could contribute to the chronic antigenic stimulation in which eBL occurs.</p><p>The presence of these additional cofactors may also induce EBV lytic cycle through B-cell reactivation and spreading EBV infection out of its natural niche of memory B-cells, characterized by a latency 0/I program[<xref rid="ppat.1005158.ref042" ref-type="bibr">42</xref>,<xref rid="ppat.1005158.ref043" ref-type="bibr">43</xref>]. In fact, in our samples we showed a non-canonical latency program of the virus characterized by a large number of cases expressing LMP-1/-2A/-2B in a significant proportion of cells along with lytic reactivation. Our results are in agreement with recent studies showing more complex EBV protein expression in Akata and Mutu cell lines, commonly used to study the role of EBV in Burkitt lymphoma[<xref rid="ppat.1005158.ref044" ref-type="bibr">44</xref>]. By using an alternative approach based on RT-QPCR array platform, Tierney <italic>et al</italic>. report a quantitative characterization of EBV transcripts in different experimental infection models that were validated in endemic Burkitt lymphoma samples[<xref rid="ppat.1005158.ref024" ref-type="bibr">24</xref>]. Interestingly, in this study a significant expression of <italic>LMP-2</italic> gene was revealed. Moreover, our results are in accordance with a previously published study in primary AIDS-related lymphomas (ARL) by Arvey and colleagues[<xref rid="ppat.1005158.ref010" ref-type="bibr">10</xref>], although a rigorous comparison is limited by the small number of ARL BLs. All together, our findings confirm recent evidence that LMP-2A cooperates in reprogramming the function of normal B-lymphocytes and enhance <italic>MYC</italic> driven lymphomagenesis through the activation of PI3K-pathway[<xref rid="ppat.1005158.ref045" ref-type="bibr">45</xref>,<xref rid="ppat.1005158.ref046" ref-type="bibr">46</xref>]. This pathway is a crucial to <italic>MYC</italic> mediated transformation as shown by PI3K/MYC transgenic mouse that produces a model that represent a phenocopy of human tumors in terms of histology, gene and protein marker expression, and somatic hypermutations[<xref rid="ppat.1005158.ref047" ref-type="bibr">47</xref>]. This scenario suggests that LMP-2A activation of PI3K is an alternative/convergent mechanism to the one driven by <italic>TCF3</italic>/<italic>ID3</italic> mutations.</p><p>The expression of genes characterizing the lytic phase of EBV found by RNA-Seq was confirmed by IHC staining for the three main genes involved in the initiation of the lytic phase, <italic>BZLF-1/ZEBRA</italic>, <italic>BMRF-1/Ea-D</italic> and <italic>BHRF-1/Ea-R</italic>. In early latent infection, EBV can be induced to enter the lytic cycle by a variety of causes including B-cell receptor stimulation, Toll-like receptor-9 activation, hypoxia, and growth factors[<xref rid="ppat.1005158.ref048" ref-type="bibr">48</xref>,<xref rid="ppat.1005158.ref049" ref-type="bibr">49</xref>]. Although lytic infection kills the host cell, it also allows horizontal spread of EBV from cell to cell and may increase the pool of latently infected B-lymphocytes from which transformed cells arise. Additionally, lytically infected B-cells secrete factors that may promote tumorigenesis, including growth and angiogenesis factors and immunosuppressive cytokines. Recent evidence has challenged the view that only the latency phase of EBV infection is significant for the development of EBV-associated malignancies, proposing that lytic EBV replication may be of pathogenic relevance.[<xref rid="ppat.1005158.ref050" ref-type="bibr">50</xref>] Humanized mice infected with lytic active viral strains develop more lymphomas than animals infected with replication-defective strains[<xref rid="ppat.1005158.ref039" ref-type="bibr">39</xref>], suggesting that lytic EBV infection may be of importance also in the context of an active immune response. In the present study we gave evidence for the first time that this occurs <italic>in vivo</italic> in the neoplastic cells of the primary tumors. Physiologically, lytic gene products are expressed in three consecutive stages: immediate-early, early, and late. Immediate-early lytic gene products initiate the process by inducing the activation of transcription of the other genes. Early genes control replication and metabolism of neoplastic cells[<xref rid="ppat.1005158.ref051" ref-type="bibr">51</xref>]. Fatty acid synthase expression is induced by the BRLF-1 immediate&#x02013;early protein, and interestingly BL tumors are characterized by altered lipid metabolism[<xref rid="ppat.1005158.ref052" ref-type="bibr">52</xref>]. Late gene products code for viral capsid antigens and proteins involved in immune evasion. <italic>BNLF-2A</italic>, detected in a significant number of our cases, may protect infected B-cells from immune recognition and elimination[<xref rid="ppat.1005158.ref053" ref-type="bibr">53</xref>]. Finally, the EBV transcriptome during the reactivation may involve the contribution of a wide array of other virus-encoded RNAs, such as BARF-0, BARF-1, BcLF-1, and RPMSI-1[<xref rid="ppat.1005158.ref054" ref-type="bibr">54</xref>], that are not translated and may function as non-coding RNA molecules which could participate in regulating gene expression[<xref rid="ppat.1005158.ref055" ref-type="bibr">55</xref>]. Heterogeneity in lytic/latent expression programs can be observed not only between patients but also within individual tumors, on a cell-to-cell basis. Intra-patient heterogeneity might be related to the activation of the immune response following the expression of the viral genes. Therefore, the tumor is under selective pressure and needs alternative mechanisms to survive and proliferate[<xref rid="ppat.1005158.ref056" ref-type="bibr">56</xref>].</p><p>Our data on the mutational landscape of eBL seems to support this hypothesis. In fact, eBL samples were characterized by a lower number of point mutations in genes previously found altered in sBL, including <italic>MYC</italic>, <italic>ID3</italic>, <italic>TCF3</italic>, <italic>DDX3X</italic>, <italic>CCND3</italic>, and <italic>TP53</italic>. These results are consistent with previous studies by Schmitz <italic>et al</italic>. [<xref rid="ppat.1005158.ref019" ref-type="bibr">19</xref>]in which <italic>TCF3/ID3</italic> mutations were more common in sBL (70% of the cases) than eBL (40%). In particular, we observed a near mutual exclusivity between <italic>TCF3/ID3</italic> mutations and the presence of EBV, indicating that TCF3 pathway is more significantly activated in EBV-negative cases.</p><p>The inverse correlation we observed between the presence and expression of EBV and the number of cellular mutations in the different BL cases, may represent an <italic>in vivo</italic> picture of the dynamic process by which a neoplastic cell, initially dependent upon EBV, switches-off viral genes and switches-on cellular mutated genes to survive and proliferate. These results are consistent with previous analysis of pediatric BL[<xref rid="ppat.1005158.ref020" ref-type="bibr">20</xref>]. Based on our findings, one should infer that eBL may arise from pathogenic pathways that are partially distinct from those driving sBL, suggesting dual mechanisms of transformation in BL, mutationally <italic>versus</italic> virally driven. On the other hand, <italic>ARID1A</italic> and <italic>RHOA</italic> were more often mutated in eBL than in sBL. <italic>ARID1A</italic> is one of the subunits of the Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex and is currently thought to behave like a tumor suppressor gene. Consistently, <italic>ARID1A</italic> mutations frequently occur as insertion/deletion, and in most of our cases involved the amino acid G1630. This gene has been reported as frequently mutated in the context of pediatric BL, with a significant association to EBV negative cases[<xref rid="ppat.1005158.ref020" ref-type="bibr">20</xref>], suggesting that the high prevalence in eBL compared to the sBL may be due to the pediatric nature of the endemic case. However, other EBV-associated cancer types show frequent deregulation of ARID1A[<xref rid="ppat.1005158.ref057" ref-type="bibr">57</xref>&#x02013;<xref rid="ppat.1005158.ref061" ref-type="bibr">61</xref>]. In particular, in EBV-associated gastric cancer a strong correlation between ARID1A deactivation and EBV presence has been reported[<xref rid="ppat.1005158.ref062" ref-type="bibr">62</xref>&#x02013;<xref rid="ppat.1005158.ref064" ref-type="bibr">64</xref>]. <italic>RHOA</italic>, which belongs to the Ras homolog family, is a small GTP-ase protein recently found to be mutated in three tumors associated with EBV infection, namely peripheral T-cell lymphoma (where it relates to follicular helper T-cells[<xref rid="ppat.1005158.ref065" ref-type="bibr">65</xref>&#x02013;<xref rid="ppat.1005158.ref067" ref-type="bibr">67</xref>]), diffuse gastric carcinoma[<xref rid="ppat.1005158.ref068" ref-type="bibr">68</xref>] and paediatric sBL[<xref rid="ppat.1005158.ref028" ref-type="bibr">28</xref>]. The distribution of <italic>RHOA</italic> mutations in our cohort overlaps with the already reported mutations (codons 5, 17, 42 and 69) suggesting a similar functional role.</p><p>Finally we identified recurrent mutations involving the amino acid R451C in one gene not previously detected in endemic or sporadic BLs, <italic>CCNF</italic>, altered in 20% of our cases. <italic>CCNF</italic> encodes a member of the cyclin family belonging to the F-box protein family; it acts as an inhibitor of centrosome reduplication during G2 phase and protects the cell from genome instability[<xref rid="ppat.1005158.ref069" ref-type="bibr">69</xref>]. Therefore, it is reasonable that <italic>CCNF</italic> mutations may cooperate in inducing lymphomagenesis by promoting chromosome instability and a hypermutator phenotype[<xref rid="ppat.1005158.ref070" ref-type="bibr">70</xref>,<xref rid="ppat.1005158.ref071" ref-type="bibr">71</xref>].</p><p>Understanding the mechanisms regulating EBV lymphomagenesis will hopefully lead to the development of highly specific therapies. To avoid the tumor evasion from the already available therapies, we need to identify and target the multiplicity of pathways that are deregulated in the neoplastic cells and decrease tumor survival and proliferation.</p></sec><sec sec-type="materials|methods" id="sec007"><title>Materials and Methods</title><sec id="sec008"><title>Cases selection</title><p>A total of 20 BL samples preserved in RNAlater (RNA stabilization Reagent-QIAGEN, Valencia, CA) were collected from the Department of Human Pathology of the Lacor Hospital (Uganda, Africa), in endemic areas. For all of them, formalin-fixed and paraffin-embedded (FFPE) samples have been available. All diagnoses were reviewed by 2 expert hematopathologists and were formulated according to the 2008 WHO classification. The clinical and histopathologic characteristics of the 20 BL cases are summarized in <xref rid="ppat.1005158.s018" ref-type="supplementary-material">S6 Table</xref>. Briefly, all cases were t(8;14)-positive, and the immunophenotype was consistent with the diagnosis of BL (CD20 positive, CD10 positive, BCL-6 positive, Ki67&#x0003e; 98%, BCL-2 negative). Epstein-Barr virus was detected by using <italic>in situ</italic> hybridization with EBER probes (INFORM EBER, Roche Diagnostics, Basel, Switzerland). EBV infection in tumor cells was observed in 100% of the samples, assessed by strong nuclear expression of small EBV-encoded RNA genes, EBER-1 and -2. These cases have been previously studied for gene expression profile analysis and showed a molecular profile consistent with molecular BL[<xref rid="ppat.1005158.ref017" ref-type="bibr">17</xref>].</p><p>We used two distinct series of cases for validation of RNA-Seq results. The first included 26 primary tumors collected at the Moi University, Eldoret (Western Kenya). Of these, 20 were used for virus data validation and 26 for EBV latency validation. The second was comprised of 66 neoplastic samples plus 7 cases for which matched normal controls were available (1 liver, 6 lymph nodes) collected from endemic area in Africa, and was used for Sequenom validation.</p></sec><sec id="sec009"><title>RNA extraction</title><p>Total RNA extraction was perfomed by RNeasy Plus Mini Kit(QIAGEN, Valencia, CA) according to the manufacture instructions. The amount and quality of RNA were evaluated by measuring the optical density (OD) at 260 nm, the 260/230 and the 260/280 ratios using a Nanodrop spectrophotometer (ND-100, Nanodrop, Thermo Scientific, Celbio, Italy).</p></sec><sec id="sec010"><title>RNA sequencing</title><p>Paired-end libraries (2x75 base pair) were prepared according to the TruSeq RNA sample preparation v2 protocol (Illumina, San Diego, USA). Briefly, 2 &#x003bc;g of Poly(A)<sup>+</sup> RNA was purified from total RNA using poly-T oligo attached magnetic beads and then used for fragmentation into 130&#x02013;290 bp fragments. First, single stranded cDNA was synthesized using reverse transcriptase (SuperScript II, Invitrogen, Life Technologies,USA) and random hexamer priming, followed by generation of double-stranded cDNA. AmpureXP beads (Beckman Coulter, Brea CA) were used to purify the ds cDNA and end repair step was performed to convert the overhangs, resulting from fragmentation, into blunt ends by 3&#x02019; to 5&#x02019; exonuclease activity. A single &#x0201c;A&#x0201d; nucleotide was added to the 3&#x02019; ends of the blunt fragments to prevent them from ligating to one another during the adapter ligation reaction. This approach was adopted to ensure a low rate of chimera (concatenated template) formation. Subsequently, sequencing adapters were added to the ends of the ds cDNA fragment and a PCR reaction was used to selectively enrich those ds cDNA fragments that had adapter molecules on both ends, amplifying the amount of ds cDNA in the final libraries. Lastly, PCR library products were purified by AmpureXP beads and quality control analysis was assessed using a DNA-1000 (Agilent, USA). The quantification was performed by Quant-it PicoGreendsDNA Assay Kit according to manufacturer&#x02019;s protocol (Invitrogen, Life Technologies,USA). The resulting libraries were sequenced on an Illumina HiScan SQ (Illumina, San Diego, USA) following the manufacturer's instructions.</p></sec><sec id="sec011"><title>Point mutation identification using RNASeq</title><p>Sequence variants were obtained using the SAVI (Statistical Algorithm for Variant Identification)[<xref rid="ppat.1005158.ref072" ref-type="bibr">72</xref>,<xref rid="ppat.1005158.ref073" ref-type="bibr">73</xref>] algorithm independently for each sample. Candidate somatic mutations were obtained by eliminating common germline variants (dbSNP 132 and variants from 10 reactive lymph nodes). Genes recurrently mutated in more than 4 samples and expressing the corresponding transcript with RPKM&#x0003e;3 were selected. Mutations occurring in the exact same position in more than 4 samples have been discarded. Conversely, genes previously reported in BL[<xref rid="ppat.1005158.ref019" ref-type="bibr">19</xref>,<xref rid="ppat.1005158.ref074" ref-type="bibr">74</xref>,<xref rid="ppat.1005158.ref075" ref-type="bibr">75</xref>] were selected, even at low recurrence, to allow the comparison between endemic and sporadic subtypes (<xref rid="ppat.1005158.s015" ref-type="supplementary-material">S3 Table</xref>). Sanger sequencing was used for technical validation.</p></sec><sec id="sec012"><title>Pandora: A pipeline for pathogen discovery using RNASeq</title><p>Characterization of the tumor microbiome is accomplished with Pandora, a new RNA-Seq pipeline for pathogen identification and discovery (<xref rid="ppat.1005158.s012" ref-type="supplementary-material">S12 Fig</xref>). The algorithm takes raw RNA-Seq data as input and outputs annotated microbial spectra present in the tumor sample. Pandora implements a subtractive algorithm consisting of discrete modules. First, the <italic>Host Removal</italic> phase sequentially aligns the input reads to the host reference using bowtie2[<xref rid="ppat.1005158.ref076" ref-type="bibr">76</xref>], blastN[<xref rid="ppat.1005158.ref077" ref-type="bibr">77</xref>] and Megablast,[<xref rid="ppat.1005158.ref078" ref-type="bibr">78</xref>] and filters out the data originating from the host. Second, the unaligned (non-host) reads are passed as input to the <italic>Microbe Identification</italic> phase where the reads are aligned to curated sets of NCBI microbial sequences representing viruses/viroids, bacteria, fungi, and select taxa of eukaryotic parasites. Third, the NCBI records matching each non-host read are input to the <italic>Reporting</italic> phase where microbial load, gene expression, and relevant clinical parameters are computed as the final output. The microbial load is computed as the number of reads mapping to the organism or virus normalized by the genome length. Gene expression quantification is computed as transcript per million (TPM)[<xref rid="ppat.1005158.ref079" ref-type="bibr">79</xref>], which provides a more accurate relative quantification of mRNA abundance compared to other normalization methods such as RPKM.</p></sec><sec id="sec013"><title>EBV genome analysis and expression</title><p>RNA-Seq reads were aligned to the GRCh37/hg19 reference genome using Bowtie2[<xref rid="ppat.1005158.ref076" ref-type="bibr">76</xref>], Blastn[<xref rid="ppat.1005158.ref077" ref-type="bibr">77</xref>] and Megablast[<xref rid="ppat.1005158.ref078" ref-type="bibr">78</xref>]. Reads not aligning to homo sapiens (non-host reads) were mapped to human herpesvirus 4, type I (NCBI accession number NC_007605.1) using TopHat, a splicing aware alignment program [<xref rid="ppat.1005158.ref080" ref-type="bibr">80</xref>] (<xref rid="ppat.1005158.s021" ref-type="supplementary-material">S9 Table</xref> and <xref rid="ppat.1005158.s022" ref-type="supplementary-material">S10 Table</xref>). EBV viral gene expression was normalized as transcripts per million (TPM)[<xref rid="ppat.1005158.ref079" ref-type="bibr">79</xref>]. For each viral product the TPM expression was normalized by the expression of A73 genes, which is consistently expressed in all the HHV4 positive BL samples. Hierarchical clustering was computed with Pearson distance and Ward&#x02019;s linkage method.</p></sec><sec id="sec014"><title>Expression analysis</title><p>Gene expression analysis was performed on both endemic and sporadic[<xref rid="ppat.1005158.ref019" ref-type="bibr">19</xref>] RNA-Seq samples of Burkitt Lymphoma. All the reads were aligned to human reference genome (GRCh37/hg19) by means of TopHat version 1.3.3. Transcript abundance quantification was computed as FPKM using Cufflinks, Cuffquant and Cuffnorm version 2.2.1[<xref rid="ppat.1005158.ref081" ref-type="bibr">81</xref>]. Hierarchical clustering was performed with Pearson distance and Ward&#x02019;s linkage method. Gene set enrichment analysis was obtained by running GSEA software on pre-ranked list of log2 ratio of the FPKM mean fold change between two conditions[<xref rid="ppat.1005158.ref082" ref-type="bibr">82</xref>].</p></sec><sec id="sec015"><title>DNA extraction</title><p>The DNA was extracted from formalin-fixed paraffin embedded (FFPE) of the original neoplastic samples using NucleoSpin Tissue (Machery-Nagel, Italy) following manufacture&#x02019;s instructions. The amount and quality of DNA were evaluated by measuring the optic density (OD) at 260 nm, the 260/230 and the 260/280 ratios using a Nanodrop spectrophotometer (ND-100, Nanodrop, Thermo Scientific, Celbio, Italy).</p></sec><sec id="sec016"><title>PCR amplification</title><p>To detect the presence of HTLV-1, CMV and KSHV, a nested PCR assay was performed on DNA of original tumor samples as previously reported[<xref rid="ppat.1005158.ref083" ref-type="bibr">83</xref>]<sup>,</sup>[<xref rid="ppat.1005158.ref084" ref-type="bibr">84</xref>] (<xref rid="ppat.1005158.s019" ref-type="supplementary-material">S7 Table</xref> and <xref rid="ppat.1005158.s020" ref-type="supplementary-material">S8 Table</xref>). DNA from HTLV-1-positive cells, CMV-positive cells, and KSHV-positive cells were used as positive controls, whereas DNA from HeLa293 cells was used as negative control. Several precautions have been taken to prevent false-positive PCR results: (a) rooms for pre- and post-PCR procedures were physically separated; (b) reagents were prepared in large batches and stored in small aliquots; (c) equipment such as the microcentrifuge, water baths, pipettes, tube racks, and other small equipment was designated for PCR work only; (d) gloves were changed frequently; and (e) aerosol-barrier pipette tips, PCR tubes, and autoclaved, diethylpyrocarbonate-treated water were sterilized by UV irradiation prior to PCR. Finally, 15 &#x003bc;l aliquots of the PCR mixture were electrophoresed on a 2% agarose gel and directly visualized by ethidium bromide staining under ultraviolet light[<xref rid="ppat.1005158.ref085" ref-type="bibr">85</xref>].</p></sec><sec id="sec017"><title>Validation in an extended panel</title><p>The MassARRAY Assay Design Suite software was used to design 8 different multiplex reactions for investigating 115 SNPs. Genotyping was performed using iPLEX Gold technology 57 MassARRAY high-throughput DNA analysis with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Sequenom), according to the manufacturer&#x02019;s protocol. 66 neoplastic cases plus 7 samples with matched normal controls (1 liver, 6 lymph nodes) were analysed.</p></sec><sec id="sec018"><title>Real-time quantitative reverse transcription PCR (RT-qPCR)</title><p>The expression of EBV-encoded genes (<italic>EBNA-1</italic>, <italic>EBNA-2</italic>, <italic>EBNA-3c</italic>, <italic>BALF-2</italic>, <italic>BALF-4</italic>, <italic>BCRF-1</italic>, <italic>BHRF-1</italic>, <italic>BILF-1</italic>, <italic>BNLF-2a</italic>, <italic>BMRF-1</italic>, <italic>BZLF-1</italic>, <italic>LMP-1</italic>, <italic>LMP-2A LF-2</italic>), which characterize the different latency programs, has been investigated on an additional series of 26 samples by RT-qPCR using the QuantiTect SYBR Green PCR Kit (Qiagen, CA) as previously reported (<xref rid="ppat.1005158.s019" ref-type="supplementary-material">S7 Table</xref>). All samples were run in triplicate. The stably expressed housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (<italic>HPRT</italic>) was used as an endogenous control and reference gene for relative quantification of each target gene. The relative expression is expressed as 2<sup>&#x00394;Ct</sup>, where &#x00394;Ct is defined as the difference in mean cycle thresholds of the gene of interest and HPRT[<xref rid="ppat.1005158.ref086" ref-type="bibr">86</xref>]. The samples were defined as &#x0201c;not expressed&#x0201d; if the &#x00394;Ct value exceeded 50 cycles[<xref rid="ppat.1005158.ref087" ref-type="bibr">87</xref>].</p></sec><sec id="sec019"><title>Immunohistochemistry</title><p>To further validate the presence of HTLV-1 and HHV-8, immunohistochemistry for viral products (HTLV-1-TAX 1: 70, Abcam, Cambridge, United Kingdom; HHV8-LANA 1: 50, Leica Biosystems, Newcastle Lid, United Kingdom; HHV8 clone AT4C11 1:50, Abnova, Taipey City, Taiwan) was performed on formalin-fixed paraffed-embedded (FFPE) sections of the original samples and in an additional series of 20 cases. CMV was detected using <italic>in situ</italic> hybridization (ISH) with Bond ISH Probe.</p><p>The protein expression of EBNA-1 (1:150, AbCam, Italy), EBNA-2 (1:100, AbCam, Italy), LMP-1 (1:100, Novus Biologicals, Italy), LMP-2A (1:100, AbCam, Italy), BZLF-1/ZEBRA (1:100, Novus Biologicals, Italy), BMRF-1/Ea-D (1:150, AbCam, Italy), BHRF-1/Ea-R (1:150, Novus Biologicals, Italy), was assessed by immunohistochemistry on FFPE sections of the original samples and on an additional series of 26 primary tumors. Sections of the samples incubated with the secondary antibody alone and sections of reactive lymphoid tissue were used as negative controls. Sections of lymph nodes with infectious mononucleosis were used as positive control. Immunoreactivity was performed on Bond Max automated immunostainer (Leica Microsystem, Bannockburn, IL, USA), with controls in parallel. No epitope retrieval was used. Ultravision Detection System using anti-Polyvalent HRP (LabVision, Fremont, CA, USA) and diaminobenzidine (DAB, Dako, Milan-Italy) as chromogen was used. Two independent investigators assessed immunoreactivity. Case were considered positive when more than 20% of the cells were stained for latent gene products and when more than 5% of the cells were stained for lytic gene products.</p></sec><sec id="sec020"><title>Ethics statement</title><p>Ethics approval for this study was obtained from the Institutional Review Board at the University of Siena (Italy), from the Ethics and Research Committee at the Lacor Hospital (Uganda) and from the Ethics and Research Committee at Moi University, Eldoret (Kenya). Written permission and informed consent have been obtained before sample collection in accordance with the Declaration of Helsinki.</p></sec></sec><sec sec-type="supplementary-material" id="sec021"><title>Supporting Information</title><supplementary-material content-type="local-data" id="ppat.1005158.s001"><label>S1 Fig</label><caption><title>Number of viral reads per million of human reads across the 20 eBL of the discovery cohort.</title><p>The red line indicates the minimal number of viral reads to detect any of the viruses in the corresponding sample.</p><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s001.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s002"><label>S2 Fig</label><caption><title>CMV detection on discovery cohort samples by IHC.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s002.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s003"><label>S3 Fig</label><caption><title>KSHV detection on discovery cohort samples by IHC.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s003.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s004"><label>S4 Fig</label><caption><title>CMV detection on Kenyan cohort samples by IHC.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s004.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s005"><label>S5 Fig</label><caption><title>KSHV detection on Kenyan cohort samples by IHC.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s005.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s006"><label>S6 Fig</label><caption><title>The specific analysis of EBV isoforms showed the presence of H2-HF splicing event.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s006.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s007"><label>S7 Fig</label><caption><title>Validation of latency and lytic genes expression by RT-qPCR for <italic>LMP-2A (A)</italic>, <italic>BZLF-1 (B)</italic>, <italic>BMRF-1 (C)</italic>, <italic>BHRF-1</italic> (D) in additional series of 26 cases is shown.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s007.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s008"><label>S8 Fig</label><caption><title>A-B Results of Sequenom analysis on an extended panel of 66 neoplastic samples <italic>plus</italic> 7 cases with matched normal controls are demonstrated.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s008.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s009"><label>S9 Fig</label><caption><title>A-C Examples of mutations in <italic>RHOA</italic> (A-B) and in <italic>CCNF</italic> (C) detected by Sequenom technology and validated by Sanger sequencing are shown.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s009.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s010"><label>S10 Fig</label><caption><title>A-F Examples of mutations in <italic>ARID1A</italic> (A), DDX3X (B), <italic>CCNF</italic> (C), <italic>RHOA</italic> (D), <italic>ID3</italic> (E), <italic>TCF3</italic> (F) detected by RNA-Seq technique and validated by Sanger sequencing are shown.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s010.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s011"><label>S11 Fig</label><caption><title>A-B The E2F, E2F3 and cell cycle G1/S gene sets presented the highest significant enrichment score together with the down-regulation of retinoblastoma pathway.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s011.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s012"><label>S12 Fig</label><caption><title>Characterization of the tumor microbiome by Pandora.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s012.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s013"><label>S1 Table</label><caption><title>(A) PCR Nested and IHC validation results on original samples. (B) IHC validation results on extended cohort from Kenya.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s013.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s014"><label>S2 Table</label><caption><title>Validation of latency type by RT-qPCR in comparison with RNA-sequencing results.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s014.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s015"><label>S3 Table</label><caption><title>Immunohistochemical results in single case.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s015.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s016"><label>S4 Table</label><caption><title>List of selected mutations detected in RNA-Seq.</title><p>(XLSX)</p></caption><media xlink:href="ppat.1005158.s016.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s017"><label>S5 Table</label><caption><title>List of variants detected through Sequenom technology.</title><p>(XLS)</p></caption><media xlink:href="ppat.1005158.s017.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s018"><label>S6 Table</label><caption><title>Clinical and histopathologic features of discovery cohort BL patients.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s018.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s019"><label>S7 Table</label><caption><title>Primers sequences for detection and typing of human lymphotropic herpesviruses.</title><p>(TIFF)</p></caption><media xlink:href="ppat.1005158.s019.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s020"><label>S8 Table</label><caption><title>Primers sequences for detection of EBV-encoded genes.</title><p>(PDF)</p></caption><media xlink:href="ppat.1005158.s020.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s021"><label>S9 Table</label><caption><title>Complete list of mutations detected in RNA-Seq.</title><p>(XLSX)</p></caption><media xlink:href="ppat.1005158.s021.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005158.s022"><label>S10 Table</label><caption><title>Table of read counts of all the human genes and transcripts detected in RNA-Seq.</title><p>(XLSX)</p></caption><media xlink:href="ppat.1005158.s022.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors would like to acknowledge Laura Pasqualucci, Riccardo Dalla Favera, and Adolfo Ferrando for helpful discussions.</p></ack><ref-list><title>References</title><ref id="ppat.1005158.ref001"><label>1</label><mixed-citation publication-type="journal"><collab>World Health O</collab> (<year>2008</year>) <article-title>Report of the ninth meeting of the WHO Technical Advisory Group on Leprosy Control: Cairo, Egypt, 6&#x02013;7 March 2008</article-title>. <source>Lepr Rev</source><volume>79</volume>: <fpage>452</fpage>&#x02013;<lpage>470</lpage>. <?supplied-pmid 19274996?><pub-id pub-id-type="pmid">19274996</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Ogwang</surname><given-names>MD</given-names></name>, <name><surname>Bhatia</surname><given-names>K</given-names></name>, <name><surname>Biggar</surname><given-names>RJ</given-names></name>, <name><surname>Mbulaiteye</surname><given-names>SM</given-names></name> (<year>2008</year>) <article-title>Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited</article-title>. <source>Int J Cancer</source>
<volume>123</volume>: <fpage>2658</fpage>&#x02013;<lpage>2663</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.23800">10.1002/ijc.23800</ext-link></comment>
<?supplied-pmid 18767045?><pub-id pub-id-type="pmid">18767045</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>van den Bosch</surname><given-names>C</given-names></name> (<year>2012</year>) <article-title>A Role for RNA Viruses in the Pathogenesis of Burkitt's Lymphoma: The Need for Reappraisal</article-title>. <source>Advances in hematology</source>
<volume>2012</volume>: <fpage>494758</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2012/494758">10.1155/2012/494758</ext-link></comment>
<?supplied-pmid 22550493?><pub-id pub-id-type="pmid">22550493</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Thorley-Lawson</surname><given-names>DA</given-names></name>, <name><surname>Hawkins</surname><given-names>JB</given-names></name>, <name><surname>Tracy</surname><given-names>SI</given-names></name>, <name><surname>Shapiro</surname><given-names>M</given-names></name> (<year>2013</year>) <article-title>The pathogenesis of Epstein-Barr virus persistent infection</article-title>. <source>Curr Opin Virol</source>
<volume>3</volume>: <fpage>227</fpage>&#x02013;<lpage>232</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.coviro.2013.04.005">10.1016/j.coviro.2013.04.005</ext-link></comment>
<?supplied-pmid 23683686?><pub-id pub-id-type="pmid">23683686</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Kelly</surname><given-names>G</given-names></name>, <name><surname>Bell</surname><given-names>A</given-names></name>, <name><surname>Rickinson</surname><given-names>A</given-names></name> (<year>2002</year>) <article-title>Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2</article-title>. <source>Nature medicine</source>
<volume>8</volume>: <fpage>1098</fpage>&#x02013;<lpage>1104</lpage>. <?supplied-pmid 12219084?><pub-id pub-id-type="pmid">12219084</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Kelly</surname><given-names>GL</given-names></name>, <name><surname>Stylianou</surname><given-names>J</given-names></name>, <name><surname>Rasaiyaah</surname><given-names>J</given-names></name>, <name><surname>Wei</surname><given-names>W</given-names></name>, <name><surname>Thomas</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature</article-title>. <source>Journal of virology</source>
<volume>87</volume>: <fpage>2882</fpage>&#x02013;<lpage>2894</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.03003-12">10.1128/JVI.03003-12</ext-link></comment>
<?supplied-pmid 23269792?><pub-id pub-id-type="pmid">23269792</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Kelly</surname><given-names>GL</given-names></name>, <name><surname>Milner</surname><given-names>AE</given-names></name>, <name><surname>Baldwin</surname><given-names>GS</given-names></name>, <name><surname>Bell</surname><given-names>AI</given-names></name>, <name><surname>Rickinson</surname><given-names>AB</given-names></name> (<year>2006</year>) <article-title>Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>
<volume>103</volume>: <fpage>14935</fpage>&#x02013;<lpage>14940</lpage>. <?supplied-pmid 17001014?><pub-id pub-id-type="pmid">17001014</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Bell</surname><given-names>AI</given-names></name>, <name><surname>Groves</surname><given-names>K</given-names></name>, <name><surname>Kelly</surname><given-names>GL</given-names></name>, <name><surname>Croom-Carter</surname><given-names>D</given-names></name>, <name><surname>Hui</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays</article-title>. <source>The Journal of general virology</source>
<volume>87</volume>: <fpage>2885</fpage>&#x02013;<lpage>2890</lpage>. <?supplied-pmid 16963746?><pub-id pub-id-type="pmid">16963746</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Niedobitek</surname><given-names>G</given-names></name>, <name><surname>Agathanggelou</surname><given-names>A</given-names></name>, <name><surname>Rowe</surname><given-names>M</given-names></name>, <name><surname>Jones</surname><given-names>EL</given-names></name>, <name><surname>Jones</surname><given-names>DB</given-names></name>, <etal>et al</etal> (<year>1995</year>) <article-title>Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma</article-title>. <source>Blood</source>
<volume>86</volume>: <fpage>659</fpage>&#x02013;<lpage>665</lpage>. <?supplied-pmid 7605996?><pub-id pub-id-type="pmid">7605996</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Arvey</surname><given-names>A</given-names></name>, <name><surname>Ojesina</surname><given-names>AI</given-names></name>, <name><surname>Pedamallu</surname><given-names>CS</given-names></name>, <name><surname>Ballon</surname><given-names>G</given-names></name>, <name><surname>Jung</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>The tumor virus landscape of AIDS-related lymphomas</article-title>. <source>Blood</source>
<volume>125</volume>: <fpage>e14</fpage>&#x02013;<lpage>e22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2014-11-599951">10.1182/blood-2014-11-599951</ext-link></comment>
<?supplied-pmid 25827832?><pub-id pub-id-type="pmid">25827832</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Dalla-Favera</surname><given-names>R</given-names></name>, <name><surname>Bregni</surname><given-names>M</given-names></name>, <name><surname>Erikson</surname><given-names>J</given-names></name>, <name><surname>Patterson</surname><given-names>D</given-names></name>, <name><surname>Gallo</surname><given-names>RC</given-names></name>, <etal>et al</etal> (<year>1982</year>) <article-title>Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>79</volume>: <fpage>7824</fpage>&#x02013;<lpage>7827</lpage>. <?supplied-pmid 6961453?><pub-id pub-id-type="pmid">6961453</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Adams</surname><given-names>JM</given-names></name>, <name><surname>Harris</surname><given-names>AW</given-names></name>, <name><surname>Pinkert</surname><given-names>CA</given-names></name>, <name><surname>Corcoran</surname><given-names>LM</given-names></name>, <name><surname>Alexander</surname><given-names>WS</given-names></name>, <etal>et al</etal> (<year>1985</year>) <article-title>The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice</article-title>. <source>Nature</source>
<volume>318</volume>: <fpage>533</fpage>&#x02013;<lpage>538</lpage>. <?supplied-pmid 3906410?><pub-id pub-id-type="pmid">3906410</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Dave</surname><given-names>SS</given-names></name>, <name><surname>Fu</surname><given-names>K</given-names></name>, <name><surname>Wright</surname><given-names>GW</given-names></name>, <name><surname>Lam</surname><given-names>LT</given-names></name>, <name><surname>Kluin</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Molecular diagnosis of Burkitt's lymphoma</article-title>. <source>N Engl J Med</source>
<volume>354</volume>: <fpage>2431</fpage>&#x02013;<lpage>2442</lpage>. <?supplied-pmid 16760443?><pub-id pub-id-type="pmid">16760443</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Neri</surname><given-names>A</given-names></name>, <name><surname>Barriga</surname><given-names>F</given-names></name>, <name><surname>Knowles</surname><given-names>DM</given-names></name>, <name><surname>Magrath</surname><given-names>IT</given-names></name>, <name><surname>Dalla-Favera</surname><given-names>R</given-names></name> (<year>1988</year>) <article-title>Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>85</volume>: <fpage>2748</fpage>&#x02013;<lpage>2752</lpage>. <?supplied-pmid 2833750?><pub-id pub-id-type="pmid">2833750</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Cario</surname><given-names>G</given-names></name>, <name><surname>Stadt</surname><given-names>UZ</given-names></name>, <name><surname>Reiter</surname><given-names>A</given-names></name>, <name><surname>Welte</surname><given-names>K</given-names></name>, <name><surname>Sykora</surname><given-names>KW</given-names></name> (<year>2000</year>) <article-title>Variant translocations in sporadic Burkitt's lymphoma detected in fresh tumour material: analysis of three cases</article-title>. <source>Br J Haematol</source>
<volume>110</volume>: <fpage>537</fpage>&#x02013;<lpage>546</lpage>. <?supplied-pmid 10997962?><pub-id pub-id-type="pmid">10997962</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Sander</surname><given-names>S</given-names></name>, <name><surname>Calado</surname><given-names>DP</given-names></name>, <name><surname>Srinivasan</surname><given-names>L</given-names></name>, <name><surname>Kochert</surname><given-names>K</given-names></name>, <name><surname>Zhang</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis</article-title>. <source>Cancer Cell</source>
<volume>22</volume>: <fpage>167</fpage>&#x02013;<lpage>179</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ccr.2012.06.012">10.1016/j.ccr.2012.06.012</ext-link></comment>
<?supplied-pmid 22897848?><pub-id pub-id-type="pmid">22897848</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Piccaluga</surname><given-names>PP</given-names></name>, <name><surname>De Falco</surname><given-names>G</given-names></name>, <name><surname>Kustagi</surname><given-names>M</given-names></name>, <name><surname>Gazzola</surname><given-names>A</given-names></name>, <name><surname>Agostinelli</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes</article-title>. <source>Blood</source>
<volume>117</volume>: <fpage>3596</fpage>&#x02013;<lpage>3608</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2010-08-301556">10.1182/blood-2010-08-301556</ext-link></comment>
<?supplied-pmid 21245480?><pub-id pub-id-type="pmid">21245480</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Schmitz</surname><given-names>R</given-names></name>, <name><surname>Ceribelli</surname><given-names>M</given-names></name>, <name><surname>Pittaluga</surname><given-names>S</given-names></name>, <name><surname>Wright</surname><given-names>G</given-names></name>, <name><surname>Staudt</surname><given-names>LM</given-names></name> (<year>2014</year>) <article-title>Oncogenic mechanisms in Burkitt lymphoma</article-title>. <source>Cold Spring Harb Perspect Med</source>
<volume>4</volume>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/cshperspect.a014282">10.1101/cshperspect.a014282</ext-link></comment>
<?supplied-pmid 24492847?><pub-id pub-id-type="pmid">24492847</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Schmitz</surname><given-names>R</given-names></name>, <name><surname>Young</surname><given-names>RM</given-names></name>, <name><surname>Ceribelli</surname><given-names>M</given-names></name>, <name><surname>Jhavar</surname><given-names>S</given-names></name>, <name><surname>Xiao</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics</article-title>. <source>Nature</source>
<volume>490</volume>: <fpage>116</fpage>&#x02013;<lpage>120</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature11378">10.1038/nature11378</ext-link></comment>
<?supplied-pmid 22885699?><pub-id pub-id-type="pmid">22885699</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Giulino-Roth</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>MacDonald</surname><given-names>TY</given-names></name>, <name><surname>Mathew</surname><given-names>S</given-names></name>, <name><surname>Tam</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes</article-title>. <source>Blood</source>
<volume>120</volume>: <fpage>5181</fpage>&#x02013;<lpage>5184</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2012-06-437624">10.1182/blood-2012-06-437624</ext-link></comment>
<?supplied-pmid 23091298?><pub-id pub-id-type="pmid">23091298</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Naresh</surname><given-names>KN</given-names></name>, <name><surname>Raphael</surname><given-names>M</given-names></name>, <name><surname>Ayers</surname><given-names>L</given-names></name>, <name><surname>Hurwitz</surname><given-names>N</given-names></name>, <name><surname>Calbi</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Lymphomas in sub-Saharan Africa&#x02014;what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research?</article-title>
<source>Br J Haematol</source>
<volume>154</volume>: <fpage>696</fpage>&#x02013;<lpage>703</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2141.2011.08772.x">10.1111/j.1365-2141.2011.08772.x</ext-link></comment>
<?supplied-pmid 21707579?><pub-id pub-id-type="pmid">21707579</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Gutierrez</surname><given-names>MI</given-names></name>, <name><surname>Bhatia</surname><given-names>K</given-names></name>, <name><surname>Barriga</surname><given-names>F</given-names></name>, <name><surname>Diez</surname><given-names>B</given-names></name>, <name><surname>Muriel</surname><given-names>FS</given-names></name>, <etal>et al</etal> (<year>1992</year>) <article-title>Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions</article-title>. <source>Blood</source>
<volume>79</volume>: <fpage>3261</fpage>&#x02013;<lpage>3266</lpage>. <?supplied-pmid 1317726?><pub-id pub-id-type="pmid">1317726</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Kelly</surname><given-names>GL</given-names></name>, <name><surname>Long</surname><given-names>HM</given-names></name>, <name><surname>Stylianou</surname><given-names>J</given-names></name>, <name><surname>Thomas</surname><given-names>WA</given-names></name>, <name><surname>Leese</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link</article-title>. <source>PLoS pathogens</source>
<volume>5</volume>: <fpage>e1000341</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1000341">10.1371/journal.ppat.1000341</ext-link></comment>
<?supplied-pmid 19283066?><pub-id pub-id-type="pmid">19283066</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Tierney</surname><given-names>RJ</given-names></name>, <name><surname>Shannon-Lowe</surname><given-names>CD</given-names></name>, <name><surname>Fitzsimmons</surname><given-names>L</given-names></name>, <name><surname>Bell</surname><given-names>AI</given-names></name>, <name><surname>Rowe</surname><given-names>M</given-names></name> (<year>2015</year>) <article-title>Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA</article-title>. <source>Virology</source>
<volume>474</volume>: <fpage>117</fpage>&#x02013;<lpage>130</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.virol.2014.10.030">10.1016/j.virol.2014.10.030</ext-link></comment>
<?supplied-pmid 25463610?><pub-id pub-id-type="pmid">25463610</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Oudejans</surname><given-names>JJ</given-names></name>, <name><surname>van den Brule</surname><given-names>AJ</given-names></name>, <name><surname>Jiwa</surname><given-names>NM</given-names></name>, <name><surname>de Bruin</surname><given-names>PC</given-names></name>, <name><surname>Ossenkoppele</surname><given-names>GJ</given-names></name>, <etal>et al</etal> (<year>1995</year>) <article-title>BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes</article-title>. <source>Blood</source>
<volume>86</volume>: <fpage>1893</fpage>&#x02013;<lpage>1902</lpage>. <?supplied-pmid 7655018?><pub-id pub-id-type="pmid">7655018</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Lear</surname><given-names>AL</given-names></name>, <name><surname>Rowe</surname><given-names>M</given-names></name>, <name><surname>Kurilla</surname><given-names>MG</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Henderson</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>1992</year>) <article-title>The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle</article-title>. <source>J Virol</source>
<volume>66</volume>: <fpage>7461</fpage>&#x02013;<lpage>7468</lpage>. <?supplied-pmid 1331531?><pub-id pub-id-type="pmid">1331531</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Vladimir</surname><given-names>Trifonov LP</given-names></name>, <name><surname>Enrico</surname><given-names>Tiacci</given-names></name>, <name><surname>Brunangelo</surname><given-names>Falini</given-names></name>, <name><surname>Raul</surname><given-names>Rabadan</given-names></name> (<year>2013</year>) <article-title>Statistical Algorithm for Variant Frequency Identification</article-title>. <source>BMC Systems Biology</source> In Press.</mixed-citation></ref><ref id="ppat.1005158.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Rohde</surname><given-names>M</given-names></name>, <name><surname>Richter</surname><given-names>J</given-names></name>, <name><surname>Schlesner</surname><given-names>M</given-names></name>, <name><surname>Betts</surname><given-names>MJ</given-names></name>, <name><surname>Claviez</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols</article-title>. <source>Genes Chromosomes Cancer</source>
<volume>53</volume>: <fpage>911</fpage>&#x02013;<lpage>916</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/gcc.22202">10.1002/gcc.22202</ext-link></comment>
<?supplied-pmid 25044415?><pub-id pub-id-type="pmid">25044415</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Sengupta</surname><given-names>S</given-names></name>, <name><surname>den Boon</surname><given-names>JA</given-names></name>, <name><surname>Chen</surname><given-names>IH</given-names></name>, <name><surname>Newton</surname><given-names>MA</given-names></name>, <name><surname>Dahl</surname><given-names>DB</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma</article-title>. <source>Cancer Res</source>
<volume>66</volume>: <fpage>7999</fpage>&#x02013;<lpage>8006</lpage>. <?supplied-pmid 16912175?><pub-id pub-id-type="pmid">16912175</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Bultema</surname><given-names>R</given-names></name>, <name><surname>Longnecker</surname><given-names>R</given-names></name>, <name><surname>Swanson-Mungerson</surname><given-names>M</given-names></name> (<year>2009</year>) <article-title>Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis</article-title>. <source>Oncogene</source>
<volume>28</volume>: <fpage>1471</fpage>&#x02013;<lpage>1476</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/onc.2008.492">10.1038/onc.2008.492</ext-link></comment>
<?supplied-pmid 19182823?><pub-id pub-id-type="pmid">19182823</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Bouchard</surname><given-names>C</given-names></name>, <name><surname>Staller</surname><given-names>P</given-names></name>, <name><surname>Eilers</surname><given-names>M</given-names></name> (<year>1998</year>) <article-title>Control of cell proliferation by Myc</article-title>. <source>Trends in Cell Biology</source>
<volume>8</volume>: <fpage>202</fpage>&#x02013;<lpage>206</lpage>. <?supplied-pmid 9695840?><pub-id pub-id-type="pmid">9695840</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Portis</surname><given-names>T</given-names></name>, <name><surname>Longnecker</surname><given-names>R</given-names></name> (<year>2004</year>) <article-title>Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway</article-title>. <source>Oncogene</source>
<volume>23</volume>: <fpage>8619</fpage>&#x02013;<lpage>8628</lpage>. <?supplied-pmid 15361852?><pub-id pub-id-type="pmid">15361852</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Scholle</surname><given-names>F</given-names></name>, <name><surname>Bendt</surname><given-names>KM</given-names></name>, <name><surname>Raab-Traub</surname><given-names>N</given-names></name> (<year>2000</year>) <article-title>Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt</article-title>. <source>J Virol</source>
<volume>74</volume>: <fpage>10681</fpage>&#x02013;<lpage>10689</lpage>. <?supplied-pmid 11044112?><pub-id pub-id-type="pmid">11044112</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Swart</surname><given-names>R</given-names></name>, <name><surname>Ruf</surname><given-names>IK</given-names></name>, <name><surname>Sample</surname><given-names>J</given-names></name>, <name><surname>Longnecker</surname><given-names>R</given-names></name> (<year>2000</year>) <article-title>Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway</article-title>. <source>J Virol</source>
<volume>74</volume>: <fpage>10838</fpage>&#x02013;<lpage>10845</lpage>. <?supplied-pmid 11044134?><pub-id pub-id-type="pmid">11044134</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Fukuda</surname><given-names>M</given-names></name>, <name><surname>Longnecker</surname><given-names>R</given-names></name> (<year>2004</year>) <article-title>Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway</article-title>. <source>J Virol</source>
<volume>78</volume>: <fpage>1697</fpage>&#x02013;<lpage>1705</lpage>. <?supplied-pmid 14747535?><pub-id pub-id-type="pmid">14747535</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Brennan</surname><given-names>P</given-names></name>, <name><surname>Mehl</surname><given-names>AM</given-names></name>, <name><surname>Jones</surname><given-names>M</given-names></name>, <name><surname>Rowe</surname><given-names>M</given-names></name> (<year>2002</year>) <article-title>Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells</article-title>. <source>Oncogene</source>
<volume>21</volume>: <fpage>1263</fpage>&#x02013;<lpage>1271</lpage>. <?supplied-pmid 11850846?><pub-id pub-id-type="pmid">11850846</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Hatton</surname><given-names>OL</given-names></name>, <name><surname>Harris-Arnold</surname><given-names>A</given-names></name>, <name><surname>Schaffert</surname><given-names>S</given-names></name>, <name><surname>Krams</surname><given-names>SM</given-names></name>, <name><surname>Martinez</surname><given-names>OM</given-names></name> (<year>2014</year>) <article-title>The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease</article-title>. <source>Immunologic research</source>
<volume>58</volume>: <fpage>268</fpage>&#x02013;<lpage>276</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12026-014-8496-1">10.1007/s12026-014-8496-1</ext-link></comment>
<?supplied-pmid 24619311?><pub-id pub-id-type="pmid">24619311</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Chene</surname><given-names>A</given-names></name>, <name><surname>Donati</surname><given-names>D</given-names></name>, <name><surname>Orem</surname><given-names>J</given-names></name>, <name><surname>Mbidde</surname><given-names>ER</given-names></name>, <name><surname>Kironde</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus</article-title>. <source>Seminars in cancer biology</source>
<volume>19</volume>: <fpage>411</fpage>&#x02013;<lpage>420</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.semcancer.2009.10.002">10.1016/j.semcancer.2009.10.002</ext-link></comment>
<?supplied-pmid 19897039?><pub-id pub-id-type="pmid">19897039</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Moormann</surname><given-names>AM</given-names></name>, <name><surname>Snider</surname><given-names>CJ</given-names></name>, <name><surname>Chelimo</surname><given-names>K</given-names></name> (<year>2011</year>) <article-title>The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma</article-title>. <source>Current opinion in infectious diseases</source>
<volume>24</volume>: <fpage>435</fpage>&#x02013;<lpage>441</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QCO.0b013e328349ac4f">10.1097/QCO.0b013e328349ac4f</ext-link></comment>
<?supplied-pmid 21885920?><pub-id pub-id-type="pmid">21885920</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Dolcetti</surname><given-names>R</given-names></name>, <name><surname>Dal Col</surname><given-names>J</given-names></name>, <name><surname>Martorelli</surname><given-names>D</given-names></name>, <name><surname>Carbone</surname><given-names>A</given-names></name>, <name><surname>Klein</surname><given-names>E</given-names></name> (<year>2013</year>) <article-title>Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas</article-title>. <source>Seminars in cancer biology</source>
<volume>23</volume>: <fpage>441</fpage>&#x02013;<lpage>456</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.semcancer.2013.07.005">10.1016/j.semcancer.2013.07.005</ext-link></comment>
<?supplied-pmid 23917255?><pub-id pub-id-type="pmid">23917255</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Biryahwaho</surname><given-names>B</given-names></name>, <name><surname>Dollard</surname><given-names>SC</given-names></name>, <name><surname>Pfeiffer</surname><given-names>RM</given-names></name>, <name><surname>Shebl</surname><given-names>FM</given-names></name>, <name><surname>Munuo</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population-based sample in Uganda</article-title>. <source>J Infect Dis</source>
<volume>202</volume>: <fpage>1347</fpage>&#x02013;<lpage>1353</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/656525">10.1086/656525</ext-link></comment>
<?supplied-pmid 20863232?><pub-id pub-id-type="pmid">20863232</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Kenney</surname><given-names>SC</given-names></name>, <name><surname>Mertz</surname><given-names>JE</given-names></name> (<year>2014</year>) <article-title>Regulation of the latent-lytic switch in Epstein-Barr virus</article-title>. <source>Semin Cancer Biol</source>
<volume>26</volume>: <fpage>60</fpage>&#x02013;<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.semcancer.2014.01.002">10.1016/j.semcancer.2014.01.002</ext-link></comment>
<?supplied-pmid 24457012?><pub-id pub-id-type="pmid">24457012</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Chene</surname><given-names>A</given-names></name>, <name><surname>Donati</surname><given-names>D</given-names></name>, <name><surname>Guerreiro-Cacais</surname><given-names>AO</given-names></name>, <name><surname>Levitsky</surname><given-names>V</given-names></name>, <name><surname>Chen</surname><given-names>Q</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>A molecular link between malaria and Epstein-Barr virus reactivation</article-title>. <source>PLoS Pathog</source>
<volume>3</volume>: <fpage>e80</fpage>
<?supplied-pmid 17559303?><pub-id pub-id-type="pmid">17559303</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>Z</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Strong</surname><given-names>MJ</given-names></name>, <name><surname>Concha</surname><given-names>M</given-names></name>, <name><surname>Baddoo</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Whole-genome sequencing of the Akata and Mutu Epstein-Barr virus strains</article-title>. <source>J Virol</source>
<volume>87</volume>: <fpage>1172</fpage>&#x02013;<lpage>1182</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.02517-12">10.1128/JVI.02517-12</ext-link></comment>
<?supplied-pmid 23152513?><pub-id pub-id-type="pmid">23152513</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Fish</surname><given-names>K</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Longnecker</surname><given-names>R</given-names></name> (<year>2014</year>) <article-title>Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma</article-title>. <source>Blood</source>
<volume>123</volume>: <fpage>530</fpage>&#x02013;<lpage>540</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2013-07-517649">10.1182/blood-2013-07-517649</ext-link></comment>
<?supplied-pmid 24174629?><pub-id pub-id-type="pmid">24174629</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Dittmer</surname><given-names>DP</given-names></name> (<year>2014</year>) <article-title>Not like a wrecking ball: EBV fine-tunes MYC lymphomagenesis</article-title>. <source>Blood</source>
<volume>123</volume>: <fpage>460</fpage>&#x02013;<lpage>461</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2013-11-537076">10.1182/blood-2013-11-537076</ext-link></comment>
<?supplied-pmid 24458272?><pub-id pub-id-type="pmid">24458272</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Sander</surname><given-names>S</given-names></name>, <name><surname>Calado</surname><given-names>DP</given-names></name>, <name><surname>Srinivasan</surname><given-names>L</given-names></name>, <name><surname>Kochert</surname><given-names>K</given-names></name>, <name><surname>Zhang</surname><given-names>BC</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis</article-title>. <source>Cancer Cell</source>
<volume>22</volume>: <fpage>167</fpage>&#x02013;<lpage>179</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ccr.2012.06.012">10.1016/j.ccr.2012.06.012</ext-link></comment>
<?supplied-pmid 22897848?><pub-id pub-id-type="pmid">22897848</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Kenney</surname><given-names>SC</given-names></name>, <name><surname>Mertz</surname><given-names>JE</given-names></name> (<year>2014</year>) <article-title>Regulation of the latent-lytic switch in Epstein-Barr virus</article-title>. <source>Seminars in cancer biology</source>
<volume>26</volume>: <fpage>60</fpage>&#x02013;<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.semcancer.2014.01.002">10.1016/j.semcancer.2014.01.002</ext-link></comment>
<?supplied-pmid 24457012?><pub-id pub-id-type="pmid">24457012</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Sivachandran</surname><given-names>N</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Frappier</surname><given-names>L</given-names></name> (<year>2012</year>) <article-title>Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection</article-title>. <source>Journal of virology</source>
<volume>86</volume>: <fpage>6146</fpage>&#x02013;<lpage>6158</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.00013-12">10.1128/JVI.00013-12</ext-link></comment>
<?supplied-pmid 22491455?><pub-id pub-id-type="pmid">22491455</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Xue</surname><given-names>SA</given-names></name>, <name><surname>Labrecque</surname><given-names>LG</given-names></name>, <name><surname>Lu</surname><given-names>QL</given-names></name>, <name><surname>Ong</surname><given-names>SK</given-names></name>, <name><surname>Lampert</surname><given-names>IA</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi</article-title>. <source>International journal of cancer Journal international du cancer</source>
<volume>99</volume>: <fpage>635</fpage>&#x02013;<lpage>643</lpage>. <?supplied-pmid 12115495?><pub-id pub-id-type="pmid">12115495</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Webster-Cyriaque</surname><given-names>J</given-names></name>, <name><surname>Tomlinson</surname><given-names>CC</given-names></name>, <name><surname>Yohe</surname><given-names>M</given-names></name>, <name><surname>Kenney</surname><given-names>S</given-names></name> (<year>2004</year>) <article-title>Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression</article-title>. <source>Journal of virology</source>
<volume>78</volume>: <fpage>4197</fpage>&#x02013;<lpage>4206</lpage>. <?supplied-pmid 15047835?><pub-id pub-id-type="pmid">15047835</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Ambrosio</surname><given-names>MR</given-names></name>, <name><surname>Piccaluga</surname><given-names>PP</given-names></name>, <name><surname>Ponzoni</surname><given-names>M</given-names></name>, <name><surname>Rocca</surname><given-names>BJ</given-names></name>, <name><surname>Malagnino</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin</article-title>. <source>PloS one</source>
<volume>7</volume>: <fpage>e44315</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0044315">10.1371/journal.pone.0044315</ext-link></comment>
<?supplied-pmid 22952953?><pub-id pub-id-type="pmid">22952953</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Jochum</surname><given-names>S</given-names></name>, <name><surname>Moosmann</surname><given-names>A</given-names></name>, <name><surname>Lang</surname><given-names>S</given-names></name>, <name><surname>Hammerschmidt</surname><given-names>W</given-names></name>, <name><surname>Zeidler</surname><given-names>R</given-names></name> (<year>2012</year>) <article-title>The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination</article-title>. <source>PLoS pathogens</source>
<volume>8</volume>: <fpage>e1002704</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1002704">10.1371/journal.ppat.1002704</ext-link></comment>
<?supplied-pmid 22615564?><pub-id pub-id-type="pmid">22615564</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Jang</surname><given-names>BG</given-names></name>, <name><surname>Jung</surname><given-names>EJ</given-names></name>, <name><surname>Kim</surname><given-names>WH</given-names></name> (<year>2011</year>) <article-title>Expression of BamHI-A Rightward Transcripts in Epstein-Barr Virus-Associated Gastric Cancers</article-title>. <source>Cancer research and treatment: official journal of Korean Cancer Association</source>
<volume>43</volume>: <fpage>250</fpage>&#x02013;<lpage>254</lpage>.<pub-id pub-id-type="pmid">22247711</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>O'Grady</surname><given-names>T</given-names></name>, <name><surname>Cao</surname><given-names>S</given-names></name>, <name><surname>Strong</surname><given-names>MJ</given-names></name>, <name><surname>Concha</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Global bidirectional transcription of the Epstein-Barr virus genome during reactivation</article-title>. <source>Journal of virology</source>
<volume>88</volume>: <fpage>1604</fpage>&#x02013;<lpage>1616</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.02989-13">10.1128/JVI.02989-13</ext-link></comment>
<?supplied-pmid 24257595?><pub-id pub-id-type="pmid">24257595</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Vereide</surname><given-names>DT</given-names></name>, <name><surname>Sugden</surname><given-names>B</given-names></name> (<year>2011</year>) <article-title>Lymphomas differ in their dependence on Epstein-Barr virus</article-title>. <source>Blood</source>
<volume>117</volume>: <fpage>1977</fpage>&#x02013;<lpage>1985</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2010-05-285791">10.1182/blood-2010-05-285791</ext-link></comment>
<?supplied-pmid 21088132?><pub-id pub-id-type="pmid">21088132</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Shain</surname><given-names>AH</given-names></name>, <name><surname>Giacomini</surname><given-names>CP</given-names></name>, <name><surname>Matsukuma</surname><given-names>K</given-names></name>, <name><surname>Karikari</surname><given-names>CA</given-names></name>, <name><surname>Bashyam</surname><given-names>MD</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>109</volume>: <fpage>E252</fpage>&#x02013;<lpage>259</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1114817109">10.1073/pnas.1114817109</ext-link></comment>
<?supplied-pmid 22233809?><pub-id pub-id-type="pmid">22233809</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Trifonov</surname><given-names>V</given-names></name>, <name><surname>Pasqualucci</surname><given-names>L</given-names></name>, <name><surname>Dalla Favera</surname><given-names>R</given-names></name>, <name><surname>Rabadan</surname><given-names>R</given-names></name> (<year>2013</year>) <article-title>MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples</article-title>. <source>BMC systems biology</source>
<volume>7</volume>: <fpage>25</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1752-0509-7-25">10.1186/1752-0509-7-25</ext-link></comment>
<?supplied-pmid 23531283?><pub-id pub-id-type="pmid">23531283</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Kan</surname><given-names>J</given-names></name>, <name><surname>Yuen</surname><given-names>ST</given-names></name>, <name><surname>Shi</surname><given-names>ST</given-names></name>, <name><surname>Chu</surname><given-names>KM</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer</article-title>. <source>Nature genetics</source>
<volume>43</volume>: <fpage>1219</fpage>&#x02013;<lpage>1223</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.982">10.1038/ng.982</ext-link></comment>
<?supplied-pmid 22037554?><pub-id pub-id-type="pmid">22037554</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Wiegand</surname><given-names>KC</given-names></name>, <name><surname>Shah</surname><given-names>SP</given-names></name>, <name><surname>Al-Agha</surname><given-names>OM</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Tse</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>ARID1A mutations in endometriosis-associated ovarian carcinomas</article-title>. <source>The New England journal of medicine</source>
<volume>363</volume>: <fpage>1532</fpage>&#x02013;<lpage>1543</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1008433">10.1056/NEJMoa1008433</ext-link></comment>
<?supplied-pmid 20942669?><pub-id pub-id-type="pmid">20942669</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Abe</surname><given-names>H</given-names></name>, <name><surname>Maeda</surname><given-names>D</given-names></name>, <name><surname>Hino</surname><given-names>R</given-names></name>, <name><surname>Otake</surname><given-names>Y</given-names></name>, <name><surname>Isogai</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability</article-title>. <source>Virchows Arch</source>
<volume>461</volume>: <fpage>367</fpage>&#x02013;<lpage>377</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00428-012-1303-2">10.1007/s00428-012-1303-2</ext-link></comment>
<?supplied-pmid 22915242?><pub-id pub-id-type="pmid">22915242</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Kan</surname><given-names>J</given-names></name>, <name><surname>Yuen</surname><given-names>ST</given-names></name>, <name><surname>Shi</surname><given-names>ST</given-names></name>, <name><surname>Chu</surname><given-names>KM</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer</article-title>. <source>Nat Genet</source>
<volume>43</volume>: <fpage>1219</fpage>&#x02013;<lpage>1223</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.982">10.1038/ng.982</ext-link></comment>
<?supplied-pmid 22037554?><pub-id pub-id-type="pmid">22037554</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Gulley</surname><given-names>ML</given-names></name> (<year>2015</year>) <article-title>Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma</article-title>. <source>Exp Mol Med</source>
<volume>47</volume>: <fpage>e134</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/emm.2014.93">10.1038/emm.2014.93</ext-link></comment>
<?supplied-pmid 25613731?><pub-id pub-id-type="pmid">25613731</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Yuen</surname><given-names>ST</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Lee</surname><given-names>SP</given-names></name>, <name><surname>Yan</surname><given-names>HH</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer</article-title>. <source>Nat Genet</source>
<volume>46</volume>: <fpage>573</fpage>&#x02013;<lpage>582</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2983">10.1038/ng.2983</ext-link></comment>
<?supplied-pmid 24816253?><pub-id pub-id-type="pmid">24816253</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Palomero</surname><given-names>T</given-names></name>, <name><surname>Couronne</surname><given-names>L</given-names></name>, <name><surname>Khiabanian</surname><given-names>H</given-names></name>, <name><surname>Kim</surname><given-names>MY</given-names></name>, <name><surname>Ambesi-Impiombato</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas</article-title>. <source>Nat Genet</source>
<volume>46</volume>: <fpage>166</fpage>&#x02013;<lpage>170</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2873">10.1038/ng.2873</ext-link></comment>
<?supplied-pmid 24413734?><pub-id pub-id-type="pmid">24413734</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Sakata-Yanagimoto</surname><given-names>M</given-names></name>, <name><surname>Enami</surname><given-names>T</given-names></name>, <name><surname>Yoshida</surname><given-names>K</given-names></name>, <name><surname>Shiraishi</surname><given-names>Y</given-names></name>, <name><surname>Ishii</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Somatic RHOA mutation in angioimmunoblastic T cell lymphoma</article-title>. <source>Nat Genet</source>
<volume>46</volume>: <fpage>171</fpage>&#x02013;<lpage>175</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2872">10.1038/ng.2872</ext-link></comment>
<?supplied-pmid 24413737?><pub-id pub-id-type="pmid">24413737</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Yoo</surname><given-names>HY</given-names></name>, <name><surname>Sung</surname><given-names>MK</given-names></name>, <name><surname>Lee</surname><given-names>SH</given-names></name>, <name><surname>Kim</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma</article-title>. <source>Nat Genet</source>
<volume>46</volume>: <fpage>371</fpage>&#x02013;<lpage>375</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2916">10.1038/ng.2916</ext-link></comment>
<?supplied-pmid 24584070?><pub-id pub-id-type="pmid">24584070</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Kakiuchi</surname><given-names>M</given-names></name>, <name><surname>Nishizawa</surname><given-names>T</given-names></name>, <name><surname>Ueda</surname><given-names>H</given-names></name>, <name><surname>Gotoh</surname><given-names>K</given-names></name>, <name><surname>Tanaka</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma</article-title>. <source>Nat Genet</source>
<volume>46</volume>: <fpage>583</fpage>&#x02013;<lpage>587</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2984">10.1038/ng.2984</ext-link></comment>
<?supplied-pmid 24816255?><pub-id pub-id-type="pmid">24816255</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>D'Angiolella</surname><given-names>V</given-names></name>, <name><surname>Esencay</surname><given-names>M</given-names></name>, <name><surname>Pagano</surname><given-names>M</given-names></name> (<year>2013</year>) <article-title>A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis</article-title>. <source>Trends Cell Biol</source>
<volume>23</volume>: <fpage>135</fpage>&#x02013;<lpage>140</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.tcb.2012.10.011">10.1016/j.tcb.2012.10.011</ext-link></comment>
<?supplied-pmid 23182110?><pub-id pub-id-type="pmid">23182110</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>D'Angiolella</surname><given-names>V</given-names></name>, <name><surname>Donato</surname><given-names>V</given-names></name>, <name><surname>Vijayakumar</surname><given-names>S</given-names></name>, <name><surname>Saraf</surname><given-names>A</given-names></name>, <name><surname>Florens</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation</article-title>. <source>Nature</source>
<volume>466</volume>: <fpage>138</fpage>&#x02013;<lpage>142</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature09140">10.1038/nature09140</ext-link></comment>
<?supplied-pmid 20596027?><pub-id pub-id-type="pmid">20596027</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>D'Angiolella</surname><given-names>V</given-names></name>, <name><surname>Donato</surname><given-names>V</given-names></name>, <name><surname>Forrester</surname><given-names>FM</given-names></name>, <name><surname>Jeong</surname><given-names>YT</given-names></name>, <name><surname>Pellacani</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair</article-title>. <source>Cell</source>
<volume>149</volume>: <fpage>1023</fpage>&#x02013;<lpage>1034</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2012.03.043">10.1016/j.cell.2012.03.043</ext-link></comment>
<?supplied-pmid 22632967?><pub-id pub-id-type="pmid">22632967</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Tiacci</surname><given-names>E</given-names></name>, <name><surname>Trifonov</surname><given-names>V</given-names></name>, <name><surname>Schiavoni</surname><given-names>G</given-names></name>, <name><surname>Holmes</surname><given-names>A</given-names></name>, <name><surname>Kern</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>BRAF mutations in hairy-cell leukemia</article-title>. <source>The New England journal of medicine</source>
<volume>364</volume>: <fpage>2305</fpage>&#x02013;<lpage>2315</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1014209">10.1056/NEJMoa1014209</ext-link></comment>
<?supplied-pmid 21663470?><pub-id pub-id-type="pmid">21663470</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Trifonov</surname><given-names>V</given-names></name>, <name><surname>Pasqualucci</surname><given-names>L</given-names></name>, <name><surname>Tiacci</surname><given-names>E</given-names></name>, <name><surname>Falini</surname><given-names>B</given-names></name>, <name><surname>Rabadan</surname><given-names>R</given-names></name> (<year>2013</year>) <article-title>SAVI: a statistical algorithm for variant frequency identification</article-title>. <source>BMC systems biology</source>
<volume>7</volume>
<issue>Suppl 2</issue>: <fpage>S2</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1752-0509-7-S2-S2">10.1186/1752-0509-7-S2-S2</ext-link></comment>
<?supplied-pmid 24564980?><pub-id pub-id-type="pmid">24564980</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Love</surname><given-names>C</given-names></name>, <name><surname>Sun</surname><given-names>Z</given-names></name>, <name><surname>Jima</surname><given-names>D</given-names></name>, <name><surname>Li</surname><given-names>G</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>The genetic landscape of mutations in Burkitt lymphoma</article-title>. <source>Nat Genet</source>
<volume>44</volume>: <fpage>1321</fpage>&#x02013;<lpage>1325</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2468">10.1038/ng.2468</ext-link></comment>
<?supplied-pmid 23143597?><pub-id pub-id-type="pmid">23143597</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Richter</surname><given-names>J</given-names></name>, <name><surname>Schlesner</surname><given-names>M</given-names></name>, <name><surname>Hoffmann</surname><given-names>S</given-names></name>, <name><surname>Kreuz</surname><given-names>M</given-names></name>, <name><surname>Leich</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing</article-title>. <source>Nat Genet</source>
<volume>44</volume>: <fpage>1316</fpage>&#x02013;<lpage>1320</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2469">10.1038/ng.2469</ext-link></comment>
<?supplied-pmid 23143595?><pub-id pub-id-type="pmid">23143595</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Langmead</surname><given-names>B</given-names></name>, <name><surname>Salzberg</surname><given-names>SL</given-names></name> (<year>2012</year>) <article-title>Fast gapped-read alignment with Bowtie 2</article-title>. <source>Nat Methods</source>
<volume>9</volume>: <fpage>357</fpage>&#x02013;<lpage>359</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nmeth.1923">10.1038/nmeth.1923</ext-link></comment>
<?supplied-pmid 22388286?><pub-id pub-id-type="pmid">22388286</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Altschul</surname><given-names>SF</given-names></name>, <name><surname>Gish</surname><given-names>W</given-names></name>, <name><surname>Miller</surname><given-names>W</given-names></name>, <name><surname>Myers</surname><given-names>EW</given-names></name>, <name><surname>Lipman</surname><given-names>DJ</given-names></name> (<year>1990</year>) <article-title>Basic local alignment search tool</article-title>. <source>J Mol Biol</source>
<volume>215</volume>: <fpage>403</fpage>&#x02013;<lpage>410</lpage>. <?supplied-pmid 2231712?><pub-id pub-id-type="pmid">2231712</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Morgulis</surname><given-names>A</given-names></name>, <name><surname>Coulouris</surname><given-names>G</given-names></name>, <name><surname>Raytselis</surname><given-names>Y</given-names></name>, <name><surname>Madden</surname><given-names>TL</given-names></name>, <name><surname>Agarwala</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Database indexing for production MegaBLAST searches</article-title>. <source>Bioinformatics</source>
<volume>24</volume>: <fpage>1757</fpage>&#x02013;<lpage>1764</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btn322">10.1093/bioinformatics/btn322</ext-link></comment>
<?supplied-pmid 18567917?><pub-id pub-id-type="pmid">18567917</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>GP</given-names></name>, <name><surname>Kin</surname><given-names>K</given-names></name>, <name><surname>Lynch</surname><given-names>VJ</given-names></name> (<year>2012</year>) <article-title>Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples</article-title>. <source>Theory in Biosciences</source>
<volume>131</volume>: <fpage>281</fpage>&#x02013;<lpage>285</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12064-012-0162-3">10.1007/s12064-012-0162-3</ext-link></comment>
<?supplied-pmid 22872506?><pub-id pub-id-type="pmid">22872506</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>Trapnell</surname><given-names>C</given-names></name>, <name><surname>Pachter</surname><given-names>L</given-names></name>, <name><surname>Salzberg</surname><given-names>SL</given-names></name> (<year>2009</year>) <article-title>TopHat: discovering splice junctions with RNA-Seq</article-title>. <source>Bioinformatics</source>
<volume>25</volume>: <fpage>1105</fpage>&#x02013;<lpage>1111</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btp120">10.1093/bioinformatics/btp120</ext-link></comment>
<?supplied-pmid 19289445?><pub-id pub-id-type="pmid">19289445</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>Trapnell</surname><given-names>C</given-names></name>, <name><surname>Williams</surname><given-names>BA</given-names></name>, <name><surname>Pertea</surname><given-names>G</given-names></name>, <name><surname>Mortazavi</surname><given-names>A</given-names></name>, <name><surname>Kwan</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation</article-title>. <source>Nat Biotechnol</source>
<volume>28</volume>: <fpage>511</fpage>&#x02013;<lpage>515</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nbt.1621">10.1038/nbt.1621</ext-link></comment>
<?supplied-pmid 20436464?><pub-id pub-id-type="pmid">20436464</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>Subramanian</surname><given-names>A</given-names></name>, <name><surname>Tamayo</surname><given-names>P</given-names></name>, <name><surname>Mootha</surname><given-names>VK</given-names></name>, <name><surname>Mukherjee</surname><given-names>S</given-names></name>, <name><surname>Ebert</surname><given-names>BL</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>102</volume>: <fpage>15545</fpage>&#x02013;<lpage>15550</lpage>. <?supplied-pmid 16199517?><pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref083"><label>83</label><mixed-citation publication-type="journal"><name><surname>Pozo</surname><given-names>F</given-names></name>, <name><surname>Tenorio</surname><given-names>A</given-names></name> (<year>1999</year>) <article-title>Detection and typing of lymphotropic herpesviruses by multiplex polymerase chain reaction</article-title>. <source>J Virol Methods</source>
<volume>79</volume>: <fpage>9</fpage>&#x02013;<lpage>19</lpage>. <?supplied-pmid 10328531?><pub-id pub-id-type="pmid">10328531</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref084"><label>84</label><mixed-citation publication-type="journal"><name><surname>Laurentino</surname><given-names>RV</given-names></name>, <name><surname>Lopes</surname><given-names>IG</given-names></name>, <name><surname>Azevedo</surname><given-names>VN</given-names></name>, <name><surname>Machado</surname><given-names>LF</given-names></name>, <name><surname>Moreira</surname><given-names>MR</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Molecular characterization of human T-cell lymphotropic virus coinfecting human immunodeficiency virus 1 infected patients in the Amazon region of Brazil</article-title>. <source>Mem Inst Oswaldo Cruz</source>
<volume>100</volume>: <fpage>371</fpage>&#x02013;<lpage>376</lpage>. <?supplied-pmid 16113884?><pub-id pub-id-type="pmid">16113884</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref085"><label>85</label><mixed-citation publication-type="journal"><name><surname>Pellett</surname><given-names>PE</given-names></name>, <name><surname>Spira</surname><given-names>TJ</given-names></name>, <name><surname>Bagasra</surname><given-names>O</given-names></name>, <name><surname>Boshoff</surname><given-names>C</given-names></name>, <name><surname>Corey</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Multicenter comparison of PCR assays for detection of human herpesvirus 8 DNA in semen</article-title>. <source>J Clin Microbiol</source>
<volume>37</volume>: <fpage>1298</fpage>&#x02013;<lpage>1301</lpage>. <?supplied-pmid 10203474?><pub-id pub-id-type="pmid">10203474</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref086"><label>86</label><mixed-citation publication-type="journal"><name><surname>Qiu</surname><given-names>J</given-names></name>, <name><surname>Smith</surname><given-names>P</given-names></name>, <name><surname>Leahy</surname><given-names>L</given-names></name>, <name><surname>Thorley-Lawson</surname><given-names>DA</given-names></name> (<year>2015</year>) <article-title>The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo</article-title>. <source>PLoS Pathog</source>
<volume>11</volume>: <fpage>e1004561</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1004561">10.1371/journal.ppat.1004561</ext-link></comment>
<?supplied-pmid 25590614?><pub-id pub-id-type="pmid">25590614</pub-id></mixed-citation></ref><ref id="ppat.1005158.ref087"><label>87</label><mixed-citation publication-type="journal"><name><surname>Bell</surname><given-names>AI</given-names></name>, <name><surname>Groves</surname><given-names>K</given-names></name>, <name><surname>Kelly</surname><given-names>GL</given-names></name>, <name><surname>Croom-Carter</surname><given-names>D</given-names></name>, <name><surname>Hui</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays</article-title>. <source>J Gen Virol</source>
<volume>87</volume>: <fpage>2885</fpage>&#x02013;<lpage>2890</lpage>. <?supplied-pmid 16963746?><pub-id pub-id-type="pmid">16963746</pub-id></mixed-citation></ref></ref-list></back></article>